Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 2862. Отображено 100.
17-05-2012 дата публикации

Apparatus and method for separating and isolating components of a biological fluid

Номер: US20120122649A1
Принадлежит: Individual

A device for separating and isolating components of a biological fluid comprising a container for containing the fluid to be processed, a tube cap assembly for closing the container while providing filling and extraction communication therewith, a float assembly disposed within the container for funneling and controlling biological fluid flow into an inverted domed shaped isolation chamber within the float and controlling the biological fluid flow out of the isolation chamber for effecting an encapsulation or a sealed isolation of at least one component or fraction of the biological fluid flow within the isolation chamber during a centrifugation process. The device further comprising a flexible tube for connecting an extraction passageway disposed within the float assembly and an extraction valve of the tube cap assembly for allowing extraction of at least the one component or fraction encapsulated or isolated within the chamber.

Подробнее
14-06-2012 дата публикации

Integrated disposable set for an apheresis system

Номер: US20120145619A1
Принадлежит: Terumo BCT Inc

An integrated pre-connected apheresis disposable set for separating plasma from blood in a separation vessel and further separating the separated plasma into desired plasma proteins in a plasma separator fluidly connected to the separation vessel to receive the separated plasma.

Подробнее
28-06-2012 дата публикации

Blood processing filter

Номер: US20120160763A1
Принадлежит: Asahi Kasei Medical Co Ltd

A blood processing filter including a flexible container (having an inlet and an outlet and a sheet-like filter member that is assembled in the flexible container) has a seal part that seals the flexible container and the filter member to form an effective filtration portion of the filter member and a partition part that seals the flexible container and the filter member to partition the effective filtration portion into a plurality of areas. The seal part and the partition part cooperate with the filter member to divide inside of the flexible container into three or more internal spaces including an inlet space that communicates with the inlet, and an outlet space that communicates with the outlet, and also form, as a blood channel, a channel that passes through each of three or more of the internal spaces and also passes multiple times through the filter member.

Подробнее
28-06-2012 дата публикации

Blood processing filter and method for priming the filter

Номер: US20120160782A1
Принадлежит: Asahi Kasei Medical Co Ltd

This invention relates to a blood processing filter including a sheet-like filter element and a flexible container having an internal space divided by the filter element. The container includes first and second container-forming-parts. The first container-forming-part includes an interior filtration space-forming-part and an exterior surrounding space-forming-part that are separated by a first seal-part. The second container-forming-part includes an extension space-forming-part surrounded by the second seal-part and arranged opposite the filter element and the surrounding space-forming-part, without being divided by the first seal-part. A port of the first container-forming-part is provided in the filtration space-forming-part and communicates with an internal space on one side defined by the filter element. The port of the second container-forming-part is provided in the extension space-forming-part and communicates with an internal space on another side defined by the filter element, and protrudes further than an outer surface of the extension space-forming-part.

Подробнее
02-08-2012 дата публикации

Apparatus and method for separating and isolating components of a biological fluid

Номер: US20120193274A1
Принадлежит: Individual

A device for separating and isolating components of a biological fluid comprising a container for containing the fluid to be processed, a tube cap assembly for closing the container while providing filling and extraction communication therewith, a float assembly disposed within the container for funneling and controlling biological fluid flow into an inverted domed shaped isolation chamber within the float and controlling the biological fluid flow out of the isolation chamber for effecting an encapsulation or a sealed isolation of at least one component or fraction of the biological fluid flow within the isolation chamber during a centrifugation process. The device further comprising a flexible tube for connecting an extraction passageway disposed within the float assembly and an extraction valve of the tube cap assembly for allowing extraction of at least the one component or fraction encapsulated or isolated within the chamber.

Подробнее
06-12-2012 дата публикации

Polymers for reversing heparin-based anticoagulation

Номер: US20120308546A1
Принадлежит: University of British Columbia

Embodiments presented herein relate to various polymers. Some of the polymer embodiments are heparin binding polymers. Some embodiments of the heparin binding polymers can be employed to bind to heparin for methods such as separating, purifying, removing, and/or isolating heparin and heparin like molecules.

Подробнее
26-09-2013 дата публикации

Recirculating fluid filtration system

Номер: US20130248450A1
Принадлежит: Deka Products LP

A fluid filtration system comprising a cross-flow filter is arranged to permit a first pump to recirculate part of the retentate of the filter to the inlet of the cross-flow filter and a second pump to return part of the permeate to the inlet of the cross-flow filter. A third pump is configured supply source fluid to the inlet of the filter. The flow path between the second pump and the cross-flow filter inlet may include an adsorption filter that may selectively remove contaminants, toxins, or pathogens in the permeate. A controller may control the first, second and third pumps to provide predetermined flow ratios among the fluid flow paths of the system in order to achieve a desired filtration level. This system may be applicable to the removal of harmful substances from blood, by first separating the plasma from the blood and then removing harmful substances from the plasma.

Подробнее
24-10-2013 дата публикации

System and Method for Collecting Platelets and Anticipating Plasma Return

Номер: US20130280342A1
Автор: Etienne Pages
Принадлежит: Haemonetics Corp

A blood processing system for collecting plasma reduced platelets and anticipating plasma return includes a venous access device, a blood component separation device, a first return line, a recirculation line, and a second return line. The venous access device draws whole blood from a subject and returns blood components to the subject using a first pump. The blood component separation device separates the drawn blood into a first blood component and a second blood component, and sends the first blood component to a first blood component bag. The first return line fluidly connects the venous-access device and the blood component separation device. The recirculation line connects the first blood component container and the separation device. The second return line fluidly connects the first blood component container and the first return line and is configured to return the first blood component within the first blood container to the subject.

Подробнее
03-01-2019 дата публикации

System and Method for Controlling Venous Air Recovery in a Portable Dialysis System

Номер: US20190001046A1
Принадлежит:

The present specification discloses a portable dialysis system comprising a mechanism that allows the user to accurately position an air bubble in a venous line, so that it can be safely removed. When an air bubble is detected, the system automatically runs the blood pump in a direction such that the air bubble is placed close to the extraction point on the venous line, from where it can safely be removed using a needleless syringe. 1. A portable dialysis system for conducting hemodialysis on a patient , the system comprising:an arterial blood line for carrying blood from the patient;a blood pump for drawing blood from said arterial line and pumping it to a dialyzer;a venous blood line for carrying purified blood from said dialyzer to said patient;a pinch clamp to prevent air in said venous line from being returned to the patient;an air bubble detector positioned in said venous blood line for detecting an air bubble arising in said venous blood line, wherein the air bubble detector is positioned within a range of 10 to 20 cm upstream of said pinch clamp and within a range of 20 to 40 cm downstream of said dialyzer;an extraction port located within a range of 10 to 20 cm upstream of said air bubble detector and within a range of 10 to 20 cm downstream of said dialyzer in the venous blood line, said extraction port being adapted to remove the said air bubble; anda controller in communication with said air bubble detector and said blood pump, said controller configured to cause said blood pump to run in a reverse direction back toward said dialyzer when an air bubble is detected, such that the air bubble is moved upstream towards the extraction port.2. The system of claim 1 , wherein the blood pump is run in a reverse direction for a specified time period.3. The system of further comprising a display with a Graphical User Interface (GUI).4. The system of claim 3 , wherein the GUI is configured to issue an alarm as soon as an air bubble is detected.5. The system of ...

Подробнее
01-01-2015 дата публикации

CRYSTALLIZED OXALATE DECARBOXYLASE AND METHODS OF USE

Номер: US20150004204A1
Принадлежит:

Oxalate decarboxylase crystals, including stabilized crystals, such as cross-linked crystals of oxalate decarboxylase, are disclosed. Methods to treat a disorder associated with elevated oxalate concentration using oxalate decarboxylase crystals are also disclosed. Additionally disclosed are methods of producing protein crystals. 18-. (canceled)9. A method of reducing oxalate in a mammal , the method comprising contacting a body fluid of the mammal with a composition comprising oxalate decarboxylase crystals in an extracorporeal device , wherein the amount of the oxalate decarboxylase crystals contained in the extracorporeal device is sufficient to reduce the oxalate.10. The method of claim 9 , wherein the oxalate decarboxylase crystals are covalently linked by a cross-linking agent.11. The method of claim 9 , wherein said crystals are active and stable in the gastrointestinal tract of the mammal.12. The method of claim 9 , wherein said crystals are active and stable at about pH 2 to about pH 8.1314-. (canceled)15. The method of claim 9 , wherein the method results in a reduction of oxalate of at least about 10%.1617-. (canceled)18. A method of treating a disorder associated with elevated oxalate concentration in a mammal claim 9 , the method comprising contacting a body fluid of the mammal with oxalate decarboxylase crystals in an extracorporeal device claim 9 , wherein the amount of the oxalate decarboxylase crystals contained in the extracorporeal device is sufficient to reduce one or more symptoms associated with the disorder.19. The method of claim 18 , wherein the disorder is related to a kidney or a liver function.20. The method of claim 18 , wherein the disorder is selected from the group consisting of primary hyperoxaluria claim 18 , enteric hyperoxaluria claim 18 , idiopathic hyperoxaluria claim 18 , and ethylene glycol poisoning.2133-. (canceled)34. The method of claim 9 , wherein the oxalate decarboxylase crystals are uncrosslinked.35. The method of ...

Подробнее
08-01-2015 дата публикации

FLUID DECONTAMINATION METHOD

Номер: US20150008192A1
Автор: Bruni Gregory J.
Принадлежит:

A method for decontaminating a biologically contaminated fluid, comprising the steps of: providing a substrate comprising an open-cell foam at least substantially coated with a solution consisting essentially of an organo-functional silane-based quarternary ammonium salt at a concentration of between approximately 0.10 percent to approximately 3.7 percent in water; at least substantially drying said solution on said substrate; placing said coated substrate in a container; introducing into said container a fluid to be decontaminated; and agitating the container for a period of time sufficient to substantially biologically decontaminate said fluid. 1. A method for decontaminating a biologically contaminated fluid , comprising the steps of:providing a substrate comprising an open-cell foam at least substantially coated with a solution consisting essentially of an organo-functional silane-based quarternary ammonium salt at a concentration of between approximately 0.10 percent to approximately 3.7 percent in water;at least substantially drying said solution on said substrate;placing said coated substrate in a container;introducing into said container a fluid to be decontaminated; andagitating the container for a period of time sufficient to substantially biologically decontaminate said fluid.2. The method of claim 1 , wherein said fluid is selected from the group consisting of biologically-contaminated drinking water claim 1 , fuels claim 1 , industrial fluids claim 1 , blood claim 1 , and blood plasma.3. The method of claim 1 , wherein the substrate is an open-cell foam characterized by 25 pores per inch.4. The method of claim 3 , wherein the open-cell foam is a reticulated polyethylene foam.5. The method of claim 3 , wherein the open-cell foam is a reticulated polyurethane foam.6. The method of claim 1 , wherein the organo-functional silane-based quarternary ammonium salt is selected from the group consisting of 3-(trihydroxysilyl) propyldimeythylloctadecyl ammonium ...

Подробнее
14-01-2021 дата публикации

METHOD FOR TREATING DRUG INTOXICATION

Номер: US20210008269A1
Принадлежит: ExThera Medical Corporation

Methods and devices are disclosed for the treatment of a subject suffering from drug intoxication by cleansing a contaminated sample from the subject with adsorption media. The adsorption media composition is selected for its antithrombogenic properties and for its ability to adhere to one or more drug targets to be reduced or eliminated. The media can further be held in a cartridge for use in extracorporeal treatments such as those of hemoperfusion. Contacting the contaminated sample from the subject with the absorption medium allows for the separation of a portion of the drug target from the sample, producing a cleansed sample that can be infused into the subject. 1. A method for treating drug intoxication or removing a toxin in a subject in need thereof , said method comprising:contacting a sample from a subject suffering from drug intoxication or other intoxication with an adsorption media comprising a combination of activated carbon and a substrate having at least one polysaccharide adsorbent to form a cleansed sample; andinfusing the cleansed sample into the subject.2. The method of claim 1 , wherein the adsorption media and the drug form an adhering complex.3. The method of claim 2 , further comprising separating the resulting sample from the adhering complex to produce a cleansed sample with a reduced amount of drug.4. The method of claim 1 , wherein the drug is a member selected from the group consisting of analgesics claim 1 , sedatives claim 1 , hypnotics claim 1 , antipsychotics claim 1 , antidepressants cardiovascular drugs claim 1 , antihistamines claim 1 , topical preparations claim 1 , cold and cough preparations claim 1 , stimulants claim 1 , street drugs claim 1 , recreational drugs claim 1 , antibiotics claim 1 , antimicrobials claim 1 , hormones claim 1 , hormone antagonists claim 1 , anticonvulsants claim 1 , gastrointestinal preparations claim 1 , dietary supplements claim 1 , and herbals.5. The method of claim 4 , wherein the drug is an ...

Подробнее
14-01-2021 дата публикации

METHOD AND DEVICE FOR THE EXTRACORPOREAL REMOVAL OF PATHOGENS AND/OR AN EXCESS OF COMPONENTS FROM A CELL SAMPLE OF A PATIENT

Номер: US20210008271A1
Автор: Schubert Walter
Принадлежит:

The invention relates to a method for the extracorporeal removal of pathogens and/or an excess of components from a cell sample of a human or animal patient suffering from an illness. The method comprises the steps: a) determination of at least one protein cluster (CMP) that is characteristic of the illness of the patient; b) preparation of the cell sample of the patient; and c) extracorporeal removal of components having the at least one determined protein cluster from the cell sample. The invention further relates to a device for carrying out said method. 1. A method for extracorporeal removal of pathogenic and/or an excess of components from a cell sample of a human or animal patient suffering from a disease including the following steps:a) determining at least one protein cluster (CMP), which is characteristic of the disease of the patient;b) providing the cell sample of the patient; andc) extracorporeal removal of components having the at least one determined CMP from the cell sample.2. The method according to claim 1 , wherein:a body fluid, and/or a tissue sample of the patient are provided as the cell sample.3. The method according to claim 1 , wherein the at least one CMP is determined based on a database and/or by means of a multi-epitope ligand cartography (MELK) and ICM method (Multi-epitope ligand cartography/imaging cycler microscopy) claim 1 , respectively claim 1 , and/or by means of a MELK robot system and/or that the extracorporeal removal of the components is monitored and/or controlled by means of a MELK and ICM method claim 1 , respectively claim 1 , and/or by means of a MELK robot system.4. The method according claim 1 , wherein the disease is a tumor disease and/or an inflammatory disease.5. The method according to claim 1 , wherein the extracorporeal removal is performed by means of an apheresis method and/or by means of an apheresis device.6. The method according to claim 5 , wherein an unselective apheresis and/or a selective apheresis and/ ...

Подробнее
14-01-2021 дата публикации

Systems and methods for optimization of plasma collection volumes

Номер: US20210008272A1
Принадлежит: Fenwal Inc

A plasmapheresis system and a method for operating a plasmapheresis system are provided by which the volume/weight of anticoagulated plasma that is collected is optimized. In one example, a nomogram is provided that utilizes the donor's hematocrit to calculate the volume/weight of raw plasma within a plasma product having the maximum volume permitted by the FDA nomogram. In a plasmapheresis procedure having multiple collection phases followed by a reinfusion cycle in which concentrated red blood cells are returned to the donor, the volume of plasma product to be collected is calculated prior to the start of each collection cycle to account for the donor's increasing hematocrit, thus resulting in a greater total volume of plasma product to be collected during the plasmapheresis procedure.

Подробнее
08-01-2015 дата публикации

METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE

Номер: US20150010929A1
Принадлежит:

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of SPARC, Follistatin-related protein 1, Tumor necrosis factor receptor superfamily member 21, Growth arrest-specific protein 1, MHC class I polypeptide-related sequence A, Syndecan-1, and WNT1-inducible-signaling pathway protein 1 as diagnostic and prognostic biomarkers in renal injuries. 1. A method for evaluating renal status in a subject , comprising:performing one or more assays configured to detect one or more biomarkers selected from the group consisting of SPARC, Follistatin-related protein 1, Tumor necrosis factor receptor superfamily member 21, Growth arrest-specific protein 1, MHC class I polypeptide-related sequence A, Syndecan-1, and WNT1-inducible-signaling pathway protein 1 by introducing a body fluid sample obtained from the subject into an assay instrument which (i) for each analyte binding assay performed, contacts all or a portion of the urine sample with a binding reagent which specifically binds for detection the kidney injury marker which is assayed, and (ii) generates one or more assay results indicative of binding of each biomarker which is assayed to its respective binding reagent;correlating the assay result(s) to the renal status of the subject, wherein said correlation step comprises correlating the assay result(s) to one or more of diagnosis, risk stratification, prognosis, classifying and monitoring of the renal status of the subject by using the assay result(s) to assign the patient to a predetermined subpopulation of individuals having a known predisposition of a current or future acute renal injury; andtreating the patient based on the predetermined subpopulation of individuals to which the ...

Подробнее
11-01-2018 дата публикации

PREPARING ANTIGEN-SPECIFIC T CELLS USING A SELF-ENCLOSED PROCESSING SYSTEM THAT CONTAINS BOTH A CENTRIFUGE AND A MAGNETIC SEPARATION COLUMN

Номер: US20180010087A1
Принадлежит: Miltenyi Biotec GmbH

The invention relates to a system, comprising: a) a sample processing unit, comprising an input port and an output port coupled to a rotating container having at least one sample chamber, the sample processing unit configured provide a first processing step to a sample or to rotate the container so as to apply a centrifugal force to a sample deposited in the chamber and separate at least a first component and a second component of the deposited sample; and b) a sample separation unit coupled to the output port of the sample processing unit, the cell separation unit comprising separation column holder (), a pump () and a plurality of valves (-) configured to at least partially control fluid flow through a fluid circuitry and a separation column () positioned in the holder, the separation column configured to separate labeled and unlabeled components of sample flowed through the column. 1. A method of enriching a defined population of target cells from a mixed population of blood cells using an apparatus that is configured for processing such cells using a sterile tubing set;wherein the tubing set comprises:(a) a first connecting member configured to receive and deliver the sample to a rotatable container,(b) said rotatable container, which is configured to rotate about an axis and thereby to apply centrifugal force to a sample contained in a processing chamber in the container so as to separate cells from the sample from other components of the sample;(c) a second connecting member configured to transfer cells processed by the rotatable container to a cell separation column;(d) said separation column, which is configured to separate labeled cells from unlabeled cells; and(e) a third connecting member configured to transfer cells separated by the cell separation column to a product collection container;wherein the method comprises:(1) delivering the sample through the first connecting member into the tubing set; and(2) operating the apparatus such that the sample is ...

Подробнее
03-02-2022 дата публикации

Cell washing apparatus

Номер: US20220031924A1
Принадлежит: HAEMAFLOW LTD, Haemair Ltd

A cell washing apparatus is provided to wash a cell-containing fluid. The apparatus is arranged to exchange one or more exchangeable entities from a cell-containing first fluid, and comprises, a first fluid conduit and a second fluid conduit, the second fluid conduit separated from the first fluid conduit by a semi-permeable membrane disposed therebetween; the first fluid conduit having a first fluid inlet and a first fluid outlet, the first fluid conduit arranged to transport the first fluid in a first direction between the first fluid inlet and the first fluid outlet; the second fluid conduit being arranged to house a second fluid; wherein the semi-permeable membrane comprises a plurality of pores arranged to permit transport of said one or more exchangeable entities from the first fluid to the second fluid; wherein the one or more exchangeable entities comprise free haemoglobin and/or blood plasma; and wherein the first fluid is whole blood isolated from a human body, or packed red blood cells. The cell washing apparatus of the present invention aims to solve the problem of harmful species that accumulate in a cell-containing fluid (such as, for example, transfusion blood) during storage and other applications, in which it is desired to transfer red blood cells to a clean suspending liquid.

Подробнее
19-01-2017 дата публикации

SYSTEM AND METHOD FOR ASPIRATING BODILY FLUID

Номер: US20170014554A1
Автор: Brennan H. George
Принадлежит:

A medical suction system and method of use is disclosed. The system may include a tube and a collection container. A distal portion of the tube may have a plurality of apertures that are disposed within the patient of an opening adjacent to an incision at a surgical site. A proximal portion of the tube extends out of the opening and is connected to the collection container. The opening is sealed around the tube so as to form a closed system with the collection container. The collection container may be resilient and form a vacuum by compressing by allowing the collection container to decompress. The collection container may also be provided to the user pre-compressed by rolling up the collection container and placing a band or wrapper around the compressed collection container. Alternatively, the collection container may be provided in the uncompressed state. Anchor tabs are used to secure the tube so that the plurality of apertures remain within the patient. 1. A bodily fluid container for collecting bodily fluid drained from a patient , the container comprising:a resilient body defining an interior cavity and provided to a user in a compressed state wherein a volume of the interior cavity is less in the compressed state compared to an uncompressed state; an input receptacle configured to form a liquid tight seal with a first end of a tube, the tube has a second end disposed on the patient to provide fluid communication from the patient to the container;', 'a one way valve for allowing fluid to flow into and not out of the interior cavity., 'an input port having2. The container of wherein the resilient body is held in the compressed state with a band.3. The container of wherein the resilient body is held in the compressed state with a wrapper.4. The container of wherein the input receptacle is a recess formed in an upper portion of the body having a cylindrical configuration claim 1 , and the recess of the input receptacle is sized to receive a tube connectable to ...

Подробнее
17-01-2019 дата публикации

Modified filter membrane and the use thereof

Номер: US20190015790A1
Принадлежит: BOEHRINGER INGELHEIM VETMEDICA GMBH

A surface-modified filter membrane for filtering blood, in particular for separating blood plasma and blood serum, and a method for the production thereof, a filter provided therewith and the use thereof.

Подробнее
21-01-2021 дата публикации

PLASMAPHERESIS DEVICE

Номер: US20210015988A1
Принадлежит:

Apparatus for treating blood. A device () for separating plasma from blood comprises a blood flow path () including formations () for agitating blood flow along the blood flow path and a separation membrane () with a first surface in fluid communication with the blood flow path. The device may be comprised in an extracorporeal blood circuit and used in a method for separating plasma from blood. 1. A device for separating plasma from blood , the device comprising:a blood flow path;a separation membrane having a first surface in fluid communication with the blood flow path; andformations located in the blood flow path for agitating blood flow along the blood flow path.2. The device of claim 1 , wherein the separation membrane is substantially permeable to blood plasma but substantially impermeable to one or more other components of blood claim 1 , such as red blood cells and platelets.3. The device of claim 2 , wherein the separation membrane has an average pore size of between 0.5 μm and 5 μm claim 2 , between 1 μm and 4 μm claim 2 , between 1.5 μm and 3 μm claim 2 , or around 2 μm.4. The device of claim 1 , wherein the separation membrane has an air flow rate at 200 Pa of at least 10 l/m claim 1 , at least 15 l/mor at least 20 l/m.5. The device of claim 1 , wherein blood flow path is formed of a substantially transparent material or comprises a substantially transparent portion.6. The device of claim 1 , wherein the separation membrane forms at least 20% claim 1 , at least 30% or at least 40% of the surface area of the blood flow path.7. The device of claim 1 , wherein the separation membrane forms a relatively lowest portion of the surface of the blood flow path.8. The device of claim 1 , wherein the ratio between the length and the width of the blood flow path may be at least 10:1 claim 1 , at least 50:1 or at least 100:1.9. The device of claim 1 , wherein the blood flow path is convoluted.10. The device of claim 9 , wherein the blood flow path is made up of ...

Подробнее
21-01-2021 дата публикации

SYSTEMS AND METHODS FOR OPTIMIZATION OF PLASMA COLLECTION VOLUMES

Номер: US20210015989A1
Принадлежит:

A plasmapheresis system and a method for operating a plasmapheresis system are provided by which the volume/weight of anticoagulated plasma that is collected is optimized. In one example, a nomogram is provided that utilizes the donor's hematocrit to calculate the volume/weight of raw plasma within a plasma product having the maximum volume permitted by the FDA nomogram. In a plasmapheresis procedure having multiple collection phases followed by a reinfusion cycle in which concentrated red blood cells are returned to the donor, the volume of plasma product to be collected is calculated prior to the start of each collection cycle to account for the donor's increasing hematocrit, thus resulting in a greater total volume of plasma product to be collected during the plasmapheresis procedure. 141.-. (canceled)42. A system for collecting plasma , comprising:a venipuncture needle configured to draw whole blood from a donor;a blood separator configured to separate the whole blood into a plasma product and a second blood component comprising red blood cells, the blood separator having a plasma output port coupled to a plasma line configured to send the plasma product to a plasma product collection container;a donor line fluidly coupled to the venipuncture needle configured to introduce the whole blood from the donor to the blood separator, flow through the donor line being controlled by a first pump;an anticoagulant line coupled to an anticoagulant source, the anticoagulant line configured to combine anticoagulant with the whole blood from the donor, flow through the anticoagulant line being controlled by a second pump;a touchscreen configured to receive input from an operator; anda controller programmed to control operation of the system, the controller coupled to the touchscreen and programmed to receive at least a donor's weight and hematocrit, to determine a target volume for plasma product and/or raw plasma, to control the system to operate a draw and return cycle to ...

Подробнее
16-01-2020 дата публикации

DIALYSIS SYSTEM HAVING INDUCTIVE HEATING

Номер: US20200016317A1
Принадлежит:

A dialysis fluid system includes a dialysis fluid inlet; a dialysis fluid outlet; a pump positioned and arranged to pump dialysis fluid through the dialysis fluid inlet and the dialysis fluid outlet; and an inductive heater located between the dialysis fluid inlet and the dialysis fluid outlet, the inductive heater including a fluid flowpath positioned and arranged to receive non-heated dialysis fluid from the dialysis fluid inlet and to output heated dialysis fluid to the a dialysis fluid outlet, a conductive heater element located within the fluid flowpath so as to be or act as a secondary coil of a transformer, and a primary coil of the transformer located outside of the fluid flowpath and positioned so as to magnetically induce a current into the conductive heater element, causing the conductive heater element and surrounding fluid to heat. 1. A dialysis fluid system comprising:a dialysis fluid inlet;a dialysis fluid outlet;a pump positioned and arranged to pump dialysis fluid through the dialysis fluid inlet and the dialysis fluid outlet; and a fluid flowpath positioned and arranged to receive non-heated dialysis fluid from the dialysis fluid inlet and to output heated dialysis fluid to the dialysis fluid outlet,', 'a conductive heater element located within the fluid flowpath so as to be or act as a secondary coil of a transformer, and', 'a primary coil of the transformer located outside of the fluid flowpath and positioned so as to magnetically induce a current into the conductive heater element, causing the conductive heater element and surrounding dialysis fluid to heat., 'an inductive heater located between the dialysis fluid inlet and the dialysis fluid outlet, the inductive heater including'}2. The dialysis fluid system of claim 1 , wherein the fluid flowpath and the conductive heater element are located within a heater housing in fluid communication with the dialysis fluid inlet and the dialysis fluid outlet.3. The dialysis fluid system of claim 2 , ...

Подробнее
17-01-2019 дата публикации

Methods for Inducing the Differentiation of Blood Monocytes into Functional Dendritic Cells

Номер: US20190017025A1
Принадлежит: YALE UNIVERSITY

Methods are provided for treating blood monocytes to produce functional antigen presenting dendritic cells. An extracorporeal quantity of a subject's blood is treated to separate the blood and produce a leukocyte concentrate comprising monocytes and plasma containing proteins. The leukocyte concentrate comprising monocytes and plasma containing proteins is pumped through a plastic treatment device, such as a photopheresis device. The resulting treated cells may be incubated for a sufficient period of time to allow the monocytes to form dendritic cells, or the treated cells may be reinfused directly to the subject.

Подробнее
22-01-2015 дата публикации

BLOOD PURIFICATION APPARATUS

Номер: US20150021244A1
Принадлежит:

A blood purification apparatus which can perform actions and operations according to the final stage of blood-return. Accordingly, a blood purification apparatus comprising a blood circuit including an arterial blood circuit and a venous blood circuit for extracorporeally circulating blood of a patient from a tip end of the arterial blood circuit to a tip end of the venous blood circuit; a blood purification means arranged between the arterial blood circuit and the venous blood circuit of the blood circuit and purifying blood flowing through the blood circuit; a substitution solution supplying means for supplying substitution solution to the blood circuit; and performing blood-return by substituting the blood in the blood circuit with the substitution solution supplied from the substitution solution supplying means after the blood purification treatment wherein the blood purification apparatus comprises a detecting means arranged at predetermined positions in the arterial blood circuit and the venous blood circuit and detecting presence or absence or blood concentration of the blood flowing in the arterial blood circuit and the venous blood circuit at said predetermined positrons, and a recognition means for recognizing a final stage of blood-return which is a condition near the end of the substitution of blood with the substitution solution based on the presence or absence of the blood or blood concentration detected by the detecting means. 1. A blood purification apparatus comprising:a blood circuit including an arterial blood circuit and a venous blood circuit for extracorporeally circulating blood of a patient from a tip end (a) of the arterial blood circuit to a tip end (b) of the venous blood circuit;a blood purification means arranged between the arterial blood circuit and the venous blood circuit of the blood circuit and purifying blood flowing through the blood circuit;a substitution solution supplying means for supplying substitution solution to the blood ...

Подробнее
22-01-2015 дата публикации

EXTRACORPOREAL BLOOD TREATMENT SYSTEM WITH HEAT RECOVERY

Номер: US20150021245A1
Принадлежит:

Blood treatment/dialysis systems are disclosed. The systems include a water treatment unit, preferably of the reverse osmosis type, whose outlet has connected thereto a water supply line provided with a number of branch connections having fluidly coupled thereto blood treatment/dialysis machines in a selective manner, and a drain line through which exhausted blood treatment fluid can be discharged from fluidly coupled blood treatment/dialysis machines. Also disclosed is a machine-external heat exchanger, which is connected to the water supply line upstream of the branch connections on one side and to the drain line on the other side. 113-. (canceled)14. An extracorporeal blood treatment system comprising: 'a water treatment unit having an outlet connected to at least one water supply line that opens into at least one line section provided with a number of branch connections and at least one drain line through which exhausted blood treatment/dialysis fluid can be discharged; and', 'a stationary system area including 'a number of blood treatment machines fluidly coupled to the branch connections and the at least one drain line in a selective manner; and', 'a non-stationary system area including{'b': 1', '1', '1', '1', '2, 'a stationary heating unit disposed externally to the blood treatment machine and comprising a first heat exchanger (WT) having one side (WT/) connected to the at least one water supply line between the water treatment unit and the line section including the branch connections, and having the other side (WT/) connected to the at least one drain line.'}15. The extracorporeal blood treatment system according to claim 14 , further comprising:{'b': '1', 'a central electronic control unit (CT) electrically connected to the blood treatment machines so as to obtain information on at least prevailing operating phases of these machines and which, in accordance with this information, controls a stationary heating unit that is connected to the at least one ...

Подробнее
22-01-2015 дата публикации

DIALYSIS SYSTEM COMPRISING HEAT RECOVERY

Номер: US20150021248A1
Автор: ALVENSLEBEN OLIVER
Принадлежит:

Dialysis systems including a water treatment unit preferably of the osmosis type, a drain line, and a heat exchanger are disclosed. A water supply line is connected to an outlet of the water treatment unit. The water supply line includes branch connections to which dialyzers are selectively fluid-coupled. Used-up dialysis fluid can be discharged from fluid-coupled dialyzers through the drain line. The heat exchanger, which is external to the dialyzers, connected on one side to the water supply line directly upstream of the branch connections and on the other side to the drain line. 18-. (canceled)9. A dialysis system comprising:a water treatment unit having an outlet connected to a water supply line that opens into at least one line section provided with branch connections to which dialyzers are fluidly coupled in a selective manner;a drain line through which the used dialysis fluid can be discharged from the fluid-coupled dialyzers; and{'b': 1', '1', '1', '1', '2, 'a first heat exchanger (WT) external to the dialyzer having one side (WT/) connected to the water supply line between the water treatment unit and the line section including the branch connections and another side (WT/) connected to the drain line.'}10. The dialysis system according to claim 9 , wherein the water supply line defines a ring line claim 9 , which claim 9 , downstream of the at least one line section including the branch connections claim 9 , is returned to the water treatment unit claim 9 , said ring line being there configured as a feedback line.11. The dialysis system according to claim 10 , further comprising a temperature transfer unit including:{'b': 2', '2', '1', '1', '2', '2, 'a second heat exchanger (WT) disposed externally to the dialyzer having one side (WT/) connected to the water supply line between the water treatment unit and the first heat exchanger (WT), and another side (WT/) connected to the feedback line between the water treatment unit and the line section including the ...

Подробнее
28-01-2016 дата публикации

METHOD FOR EXTRACORPOREAL REMOVAL OF PATHOGENIC MICROBE, AN INFLAMMATORY CELL OR AN INFLAMMATORY PROTEIN FROM BLOOD

Номер: US20160022898A1
Автор: BERGSTROM Tomas, LARM Olle
Принадлежит: ExThera Medical Corporation

The present invention relates to a method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from mammalian blood/use of a device comprising a carbohydrate immobilized on a solid substrate, said carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, for extracorporeal removal of said pathogenic microbe, inflammatory cell or inflammatory protein from mammalian blood/use of a carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, wherein said carbohydrate is immobilized on a solid substrate, in the preparation of a device for treatment of a condition caused or aggravated by said pathogenic microbe, inflammatory cell or inflammatory protein and a method for treatment of a mammalian subject suffering from a condition caused or aggravated by a pathogenic microbe, an inflammatory cell or an inflammatory protein. 1. A method for treating a subject in need thereof , by extracorporeal removal of a pathogenic microbe , an inflammatory cell or an inflammatory protein , said method comprising:a) contacting said subject's whole blood with heparin immobilized on a solid substrate, wherein said heparin is covalently linked by end-point attachment under conditions allowing binding of said pathogenic microbe, said inflammatory cell or said inflammatory protein to the heparin;b) separating the whole blood from the solid substrate; andc) recovering said whole blood containing a reduced amount of said pathogenic microbe, said inflammatory cell or said inflammatory protein.2. The method of claim 1 , further comprising: d) reintroducing into said subject said whole blood containing a reduced amount of said pathogenic microbe claim 1 , said inflammatory cell or said inflammatory protein.3. The method of claim 1 , wherein said solid substrate comprises microparticles.4. The method of claim 1 , wherein said solid substrate ...

Подробнее
10-02-2022 дата публикации

INCREASING RESPONSES TO CHECKPOINT INHIBITORS BY EXTRACORPOREAL APHERESIS

Номер: US20220041729A1
Принадлежит: IMMUNICOM, INC.

The invention provides means, methods, and compositions of matter useful for enhancing tumor response to checkpoint inhibitors. In one embodiment, the invention teaches utilization of extracorporeal apheresis, specifically removal of various tumor derived, or tumor microenvironment derived immunological “blocking factors”. In one embodiment the invention provides the removal of soluble TNF-alpha receptors (sTNF-Rs) as a means of augmenting efficacy of immune checkpoint inhibitors. In one specific embodiment removal of sTNF-Rs is utilized to enhance efficacy of inhibitors of the PD-1/PD-L1 pathway, and/or the CD28/CTLA-4 pathway. 118-. (canceled)19. A method of enhancing an efficacy of an antibody administered to a patient , comprising the steps of:(a) administering an antibody capable of suppressing activity of a PD-L2 molecule; and(b) extracorporeally removing an immunological blocking factor that inhibits the effectiveness of the antibody from blood or a blood component of the patient.20. The method of claim 19 , wherein the antibody is selected from the group consisting of AMP-224 and rHIgM12B7.21. The method of claim 19 , wherein the immunological blocking factor is a soluble tumor necrosis factor (TNF)-alpha receptor.22. The method of claim 21 , wherein step (b) is performed using an affinity capture substrate that comprises an immobilized TNF-alpha molecule comprising one or more of a native TNF-alpha molecule and a mutated TNF-alpha molecule.23. The method of claim 22 , wherein the immobilized TNF-alpha molecule is a trimer.24. The method of claim 19 , further comprising after step (b) administering an antibody capable of suppressing activity of a PD-L2 molecule one or more additional times to the patient.25. The method of claim 19 , further comprising after step (b) extracorporeally removing one or more additional times an immunological blocking factor that inhibits the effectiveness of the antibody from blood or a blood component of the patient.26. The ...

Подробнее
10-02-2022 дата публикации

INCREASING RESPONSES TO CHECKPOINT INHIBITORS BY EXTRACORPOREAL APHERESIS

Номер: US20220041730A1
Принадлежит: IMMUNICOM, INC.

The invention provides means, methods, and compositions of matter useful for enhancing tumor response to checkpoint inhibitors. In one embodiment, the invention teaches utilization of extracorporeal apheresis, specifically removal of various tumor derived, or tumor microenvironment derived immunological “blocking factors”. In one embodiment the invention provides the removal of soluble TNF-alpha receptors (sTNF-Rs) as a means of augmenting efficacy of immune checkpoint inhibitors. In one specific embodiment. removal of sTNF-Rs is utilized to enhance efficacy of inhibitors of the PD-1/PD-L1 pathway, and/or the CD28/CTLA-4 pathway. 118-. (canceled)19. A method of enhancing an efficacy of an antibody administered to a patient , comprising the steps of:(a) administering an antibody capable of suppressing activity of a checkpoint protein selected from the group consisting of B7-H3 and B7-H4; and(b) extracorporeally removing an immunological blocking factor that inhibits the effectiveness of the antibody from blood or a blood component of the patient.20. The method of claim 19 , wherein the antibody is MGA271.21. The method of claim 19 , wherein the immunological blocking factor is a soluble tumor necrosis factor (TNF)-alpha receptor.22. The method of claim 21 , wherein the step of extracorporeally removing the soluble TNF-alpha receptor alpha receptor is performed using an affinity capture substrate that comprises an immobilized TNF-alpha molecule comprising one or more of a native TNF-alpha molecule and a mutated TNF-alpha molecule.23. The method of claim 22 , wherein the immobilized TNF-alpha molecule is a trimer.24. The method of claim 19 , further comprising after step (b) administering an antibody capable of suppressing activity of a checkpoint protein selected from the group consisting of B7-H3 and B7-H4 one or more additional times to the patient.25. The method of claim 19 , further comprising after step (b) extracorporeally removing one or more additional times ...

Подробнее
10-02-2022 дата публикации

INCREASING RESPONSES TO CHECKPOINT INHIBITORS BY EXTRACORPOREAL APHERESIS

Номер: US20220041731A1
Принадлежит: IMMUNICOM, INC.

The invention provides means, methods, and compositions of matter useful for enhancing tumor response to checkpoint inhibitors. In one embodiment, the invention teaches utilization of extracorporeal apheresis, specifically removal of various tumor derived, or tumor microenvironment derived immunological “blocking factors”. In one embodiment the invention provides the removal of soluble TNF-alpha receptors (sTNF-Rs) as a means of augmenting efficacy of immune checkpoint inhibitors. In one specific embodiment removal of sTNF-Rs is utilized to enhance efficacy of inhibitors of the PD-1/PD-L1 pathway, and/or the CD28/CTLA-4 pathway. 118-. (canceled)19. A method of enhancing an efficacy of an antibody administered to a patient , comprising the steps of:(a) administering an antibody capable of suppressing activity of a checkpoint protein selected from a group consisting of a LAG3, a Tim3, a 2B4, a A2aR, a ID02, a BTLA, a DR3, a GAL9, a HVEM, a ID01, a KIR, a LAIR, a LIGHT, a MARCO, a PS, a SLAM, a TIGIT, a VISTA, a VTCN1, a CD2, a CD20, a CD30, a CD33, a CD52, a CD70, a CD112, a CD160, and a CD226 molecule;(b) extracorporeally removing an immunological blocking factor that inhibits the effectiveness of the antibody from blood or a blood component of the patient.20. The method of claim 19 , wherein the antibody is selected from a group consisting of IMP321 claim 19 , ibritumomab tiuxetan claim 19 , ofatumumab claim 19 , rituximab claim 19 , obinutuzumab claim 19 , tositumomab claim 19 , brentuximab vedotin claim 19 , gemtuzumab ozogamicin claim 19 , and alemtuzumab.21. The method of claim 19 , wherein the immunological blocking factor is a soluble tumor necrosis factor (TNF)-alpha receptor.22. The method of claim 21 , wherein step (b) is performed using an affinity capture substrate that comprises an immobilized TNF-alpha molecule comprising one or more of a native TNF-alpha molecule and a mutated TNF-alpha molecule.23. The method of claim 22 , wherein the immobilized TNF- ...

Подробнее
10-02-2022 дата публикации

INCREASING RESPONSES TO CHECKPOINT INHIBITORS BY EXTRACORPOREAL APHERESIS

Номер: US20220041732A1
Принадлежит: IMMUNICOM, INC.

The invention provides means, methods, and compositions of matter useful for enhancing tumor response to checkpoint inhibitors. In one embodiment, the invention teaches utilization of extracorporeal apheresis, specifically removal of various tumor derived, or tumor microenvironment derived immunological “blocking factors”. In one embodiment the invention provides the removal of soluble TNF-alpha receptors (sTNF-Rs) as a means of augmenting efficacy of immune checkpoint inhibitors. In one specific embodiment removal of sTNF-Rs is utilized to enhance efficacy of inhibitors of the PD-1/PD-L1 pathway, and/or the CD28/CTLA-4 pathway. 118-. (canceled)19. A method of enhancing an efficacy of an antibody administered to a patient , comprising the steps of:(a) administering an antibody capable of suppressing activity of a CTLA-4 molecule; and(b) extracorporeally removing an immunological blocking factor that inhibits the effectiveness of the antibody from blood or a blood component of the patient.20. The method of claim 19 , wherein the antibody is selected from the group consisting of ipilimumab claim 19 , tremelimumab claim 19 , and BNI3.21. The method of claim 19 , wherein the immunological blocking factor is a soluble tumor necrosis factor (TNF)-alpha receptor.22. The method of claim 21 , wherein step (b) is performed using an affinity capture substrate that comprises an immobilized TNF-alpha molecule comprising one or more of a native TNF-alpha molecule and a mutated TNF-alpha molecule.23. The method of claim 22 , wherein the immobilized TNF-alpha molecule is a trimer.24. The method of claim 19 , further comprising after step (b) administering an antibody capable of suppressing activity of a CTLA-4 molecule one or more additional times to the patient.25. The method of claim 19 , further comprising after step (b) extracorporeally removing one or more additional times an immunological blocking factor that inhibits the effectiveness of the antibody from blood or a blood ...

Подробнее
23-01-2020 дата публикации

COLLATERAL FLOW CHANNEL SEALANT DELIVERY METHODS AND SYSTEMS

Номер: US20200022706A1
Принадлежит: PulmonX Corporation

Devices, methods, and systems are provided for occluding a collateral flow channel between a target lung compartment and an adjacent lung compartment. A video-assisted thoracoscopic device is inserted into a thoracic cavity of a patient and positioned at a fissure between a target lung compartment and an adjacent lung compartment. A collateral flow channel between the target lung compartment and the adjacent lung compartment is then identified using the video-assisted thoracoscopic device and an agent is injected into the collateral flow channel, thereby reducing the collateral flow channel. 1. (canceled)2. A method for occluding a collateral flow channel between a target lung compartment and an adjacent lung compartment , said method comprising:inserting a video-assisted thoracoscopic device into a thoracic cavity of a patient; andcutting tissue at a collateral flow channel between a target lung compartment and an adjacent lung compartment from the thoracic cavity thereby disrupting the collateral flow channel.3. The method of claim 2 , further comprising stapling claim 2 , suturing claim 2 , or gluing the cut tissue.4. The method of claim 2 , further comprising identifying the collateral flow channel using the video-assisted thoracoscopic device.5. A method as in claim 2 , further comprising placing an endobronchial valve within an airway leading to the target lung compartment.6. A method as in claim 5 , wherein the endobronchial valve is a one-way flow control valve configured to allow air to flow out of the target lung compartment and prevent air flow into the target lung compartment.7. A method for occluding a collateral flow channel between a target lung compartment and an adjacent lung compartment claim 5 , said method comprising:inserting a video-assisted thoracoscopic device into a thoracic cavity of a patient;inserting a needle into the thoracic cavity and through tissue forming a collateral flow channel between a target lung compartment and an adjacent ...

Подробнее
23-01-2020 дата публикации

SYSTEMS, DEVICES, AND METHODS FOR BODILY FLUID SEPARATION MATERIALS

Номер: US20200023318A1
Принадлежит:

In one embodiment described herein, a bodily fluid separation material is provided comprising a formed component capture region and a bodily fluid pass-through region. The pass-through region has structures with a reduced liquid leaching quality relative to than the capture region, wherein during separation material use, bodily fluid enters the capture region prior to entering the pass-through region. Optionally, a bodily fluid pass-through region has a reduced amount of liquid leaching material relative to than the capture region. 125-. (canceled)26. A filter device comprising:a bodily fluid separation material comprising a first capture region formed of a first material and having an anti-hemolytic surface coating not comprising the first material;a second capture region formed of the first material and without the anti-hemolytic surface coating not comprising the first material;a bodily fluid pass-through region formed of the first material and comprising pass-through openings sized so that formed components of the bodily fluid do not enter the bodily fluid pass-through region.2725. The device of claim wherein at least a portion of the separation material comprises an asymmetric polyethersulfone.2825. The device of claim wherein at least a portion of the separation material comprises polyarylethersulfone.2925. The device of claim wherein at least a portion of the separation material comprises an asymmetric polyarylethersulfone.3025. The device of claim wherein at least a portion of the separation material comprises a polysulfone.3125. The device of claim wherein the separation material comprises an asymmetric polysulfone.3225. The device of claim wherein the anti-hemolytic surface coating comprises single and/or double alkyl chain N-oxides of tertiary amines (NTA).34. The device of wherein the separation material comprises at least two separate separation materials.35. The device of further comprising at least another region of the separation material between the ...

Подробнее
02-02-2017 дата публикации

Dialysis system including automatic priming

Номер: US20170028120A1

A hemodialysis system comprising: a source of priming fluid; an extracorporeal circuit including an arterial line, a venous line, and a drip chamber; a level sensor operable with the drip chamber; a reversible blood pump operable with the extracorporeal circuit; a connection between the arterial and the venous line; and a priming sequence in which priming fluid from the source is pumped in a reverse pump direction through the extracorporeal circuit and reversibly in a normal pump direction through the extracorporeal circuit, wherein an output from the level sensor is used to determine when to stop pumping in at least one of the directions.

Подробнее
30-01-2020 дата публикации

BLOOD COMPONENT COLLECTION CASSETTE AND MANUFACTURING METHOD OF THE SAME

Номер: US20200030505A1
Автор: IGARASHI Masatsugu
Принадлежит: TERUMO KABUSHIKI KAISHA

A blood component collection cassette that can trap a substance where blood components coagulate by using a simple and economical configuration, and a manufacturing method of the blood component collection cassette are provided. 1. A blood component collection cassette which includes a cassette main body , where a flow path is formed , and is configured to be mountable to a blood component separation device , whereinthe cassette main body is formed of a soft material, anda filter member for trapping a substance where blood components coagulate is arranged on the flow path in the cassette main body.2. The blood component collection cassette according to claim 1 , whereinthe cassette main body has a filter housing unit that houses the filter member, andthe filter member is fixed to an inner circumferential portion of the filter housing unit.3. The blood component collection cassette according to claim 1 , whereinthe cassette main body has a first sheet and a second sheet which are formed of a soft material, the first sheet and the second sheet are superposed in a thickness direction and bonded to each other, and the flow path is formed between the first sheet and the second sheet.4. The blood component collection cassette according to claim 3 , whereinan engaging portion attachable to and detachable from a distal end portion of a blow nozzle which is used when the cassette main body is blow-molded is provided to the filter member.5. The blood component collection cassette according to claim 1 , whereinan engaging portion attachable to and detachable from a distal end portion of a tool which is used when the cassette main body is formed is provided to the filter member.6. The blood component collection cassette according to claim 4 , whereinthe filter member has a cylindrical filter main body of which one end is provided with an opening portion and of which another end is provided with a bottom portion, andthe engaging portion protrudes from the other end of the filter ...

Подробнее
05-02-2015 дата публикации

MEDICAL APPARATUS FOR EXTRACORPOREAL TREATMENT OF FLUID AND A PROCESS OF CALCULATING SET FLOW RATES IN A MEDICAL APPARATUS FOR DELIVERY OR COLLECTION OF FLUIDS

Номер: US20150034536A1
Принадлежит: GAMBRO LUNDIA AB

An apparatus for extracorporeal treatment of fluid and a process of setting up a medical apparatus for the delivery or collection of fluids are disclosed. According to the apparatus and the process, a control unit () is configured calculate set values of two or more of the fluid flow rates by imposing that an emptying time of containers of fresh fluid () and/or a filling time of a waste container is substantially same as, or multiple of the emptying time of one or more of the other containers of fresh fluid. 1. An apparatus for extracorporeal treatment of fluid comprising:a filtration unit having a primary chamber and a secondary chamber separated by a semi-permeable membrane;a blood withdrawal line connected to an inlet of the primary chamber, and a blood return line connected to an outlet of the primary chamber said blood lines being configured for connection to a patient cardiovascular system;a blood pump configured to control the flow of blood through the blood lines;an effluent fluid line connected, at one end thereof, to an outlet of the secondary chamber and at its other end to a waste container; a pre-dilution infusion fluid line connected at one end thereof to the blood withdrawal line and at its other end to a first container of fresh fluid,', 'a post-dilution infusion fluid line connected at one end thereof to the blood return line and at its other end to a second container of fresh fluid,', 'a dialysis fluid line connected at one end thereof to the inlet of the secondary chamber and at its other end to a third container of fresh fluid,', 'a pre-blood pump infusion fluid line connected at one end thereof to a fourth container of fresh fluid and at its other end to the blood withdrawal line in a region of this latter which is positioned in use upstream the blood pump,', 'one or more syringe lines connected at one end thereof either to the blood withdrawal line or to the blood return line or directly to the patient, and at its other end to a syringe ...

Подробнее
05-02-2015 дата публикации

APPARATUS FOR EXTRACORPOREAL TREATMENT OF BLOOD AND PROCESS OF CALCULATING SET FLOW RATES IN A MEDICAL APPARATUS FOR DELIVERY OR COLLECTION OF FLUIDS

Номер: US20150034557A1
Автор: Pouchoulin Dominique
Принадлежит: GAMBRO LUNDIA AB

An apparatus for extracorporeal treatment of fluid and a process of setting up a medical apparatus for the delivery or collection of fluids are disclosed. According to the apparatus and the process, a control unit () is configured calculate set values of two or more of the fluid flow rates based on a fluid flow rate set by the operator and on a prescribed dose value (D). 1. An apparatus for extracorporeal treatment of blood comprising:a filtration unit having a primary chamber and a secondary chamber separated by a semi-permeable membrane;a blood withdrawal line connected to an inlet of the primary chamber, and a blood return line connected to an outlet of the primary chamber said blood lines being configured for connection to a patient cardiovascular system;a blood pump configured to control the flow of blood through the blood lines;an effluent fluid line connected to an outlet of the secondary chamber; a pre-dilution infusion fluid line connected at one end thereof to the blood withdrawal line,', 'a post-dilution infusion fluid line connected at one end thereof to the blood return line,', 'a dialysis fluid line connected at one end thereof to the inlet of the secondary chamber,', 'a pre-blood pump infusion fluid line connected at one end thereof to the blood withdrawal line in a region of this latter which is positioned in use upstream the blood pump,, 'at least two further fluid lines selected in the group comprisingmeans for regulating the flow of fluid through said fluid lines; anda control unit connected to the means for regulating, the control unit being configured to execute a flow-rate setup procedure comprising: [{'sub': 'rep1', 'a fluid flow rate (Q) through the pre-dilution infusion fluid line,'}, {'sub': 'rep2', 'a fluid flow rate (Q) through the post-infusion fluid line,'}, {'sub': 'pbp', 'a fluid flow rate (Q) through the pre-blood pump infusion fluid line,'}, {'sub': 'dial', 'a fluid flow rate (Q) through the dialysis liquid fluid line, and'}, {'sub ...

Подробнее
04-02-2021 дата публикации

COMBINATION OF A WOUND-RINSING SOLUTION AND COLD PLASMA FOR THE TREATMENT OF WOUNDS

Номер: US20210030596A1
Автор: Rotering Heinrich
Принадлежит:

The present invention relates to the use of a combination of a wound-rinsing solution and cold atmospheric plasma for treating wounds. The present invention further relates to a method for treating wounds, comprising rinsing the wound with a wound solution and treating the wound with cold atmospheric plasma. 1. Use of a combination of a wound-rinsing solution and cold atmospheric plasma for treating wounds , wherein a vacuum activated carbon dressing is used.2. Use according to claim 1 , wherein the activated carbon-containing part of the activated carbon dressing is applied directly to the wound.3. Method for treating wounds claim 1 , comprising the following steps:(a) rinsing the wound with a wound-rinsing solution, and(b) treating the wound with cold atmospheric plasma.4. Method according to claim 3 , further comprising(c) repeated rinsing of the wound with a wound-rinsing solution.5. Method according to either or claim 3 , further comprising(d) applying a vacuum activated carbon dressing to the wound.6. Method according to any of to claim 3 , further comprising treating the wound-rinsing solution remaining on the wound with cold atmospheric plasma.7. Use according to either or claim 3 , or method according to any of to claim 3 , wherein the wound-rinsing solution contains reactive oxygen.8. Use according to any of claim 3 , or claim 3 , or method according to any of to claim 3 , wherein the wound-rinsing solution contains singlet oxygen.9. Use according to any of claim 3 , claim 3 , or claim 3 , or method according to any of to claim 3 , wherein ambient air or argon is used for plasma generation.10. Use according to any of claim 3 , claim 3 , or to claim 3 , or method according to any of to claim 3 , wherein the salt content of the wound-rinsing solution is less than 4% by weight. This application claims priority to International Application No. PCT/EP2019/051680, filed on Jan. 24, 2019, which claims the benefit of German Application No. 10 2018 101 748.0, filed ...

Подробнее
04-02-2021 дата публикации

DEVICES, SYSTEMS AND METHODS FOR THE BROAD-SPECTRUM REDUCTION OF PRO-INFLAMMATORY CYTOKINES IN BLOOD

Номер: US20210030942A1
Принадлежит:

Devices, systems and methods for the broad-spectrum reduction of pro-inflammatory cytokines in blood. The pro-inflammatory cytokines can be freely circulating in the blood as well as cytokines that are transported within or bound to the surface of particles collectively referred to as CytoVesicles while simultaneously adsorbing toxins and pathogens from blood and blood plasma. A plasma separation column with binding, capture and adsorbent components optimize the removal of cytokines and CytoVesicles from blood while minimizing the removal of essential blood elements. Adsorbent components are incorporated within the extra-lumen space, outside of the plasma fiber walls and within the outer shell of the column and can include activated carbon, ion exchange resins and non-ionic exchange resins. The resulting devices, systems and methods alleviate the symptoms or severity of a wide range of disease conditions associated with an abnormal production or dysregulation of pro-inflammatory cytokines. 1. An extracorporeal system for the removal of inflammatory agents from blood , comprising:a housing;a hollow fiber filter disposed within said housing; said filter comprising a plurality of pores sized and dimensioned to permit passage of inflammatory agents having a diameter between about 0.5 nanometers and 6000 nanometers; andat least one adsorption component positioned inside the housing and outside the hollow fiber in an extra-lumen space.2. The extracorporeal system of claim 1 , wherein adsorption component is selected from the group consisting of activated carbon claim 1 , non-ionic exchange resin and ion exchange resin.3. The extracorporeal system of claim 1 , wherein said inflammatory agents are selected from the group consisting of cytokines claim 1 , proteins with surface bound cytokines claim 1 , cytovesicles with encapsulated cytokine cargos claim 1 , cytovesicles with surface bound cytokines claim 1 , pathogens claim 1 , endotoxins claim 1 , and exotoxins.4. The ...

Подробнее
04-02-2021 дата публикации

Combined Bio-Artificial Liver Support System

Номер: US20210030943A1

A combined bio-artificial liver support system, includes branch tubes that are connected in sequence: a blood input branch tube, an upstream tail end, a first plasma separation branch tube comprising at least a first plasma separator, a non-biological purification branch tube comprising at least a plasma perfusion device and a bilirubin adsorber, a biological purification branch tube comprising at least a hepatocyte culture cartridge assembly, and a plasma return branch tube, a downstream tail end of which is set as a blood output end. 1. A combined bio-artificial liver support system , comprising a plurality of branch tubes that are connected in sequence: a blood input branch tube , an upstream tail end of which is set as a blood input end , a first plasma separation branch tube comprising at least a first plasma separator , a non-biological purification branch tube comprising at least a plasma perfusion device and a bilirubin adsorber , a biological purification branch tube comprising at least a hepatocyte culture cartridge assembly , and a plasma return branch tube , a downstream tail end of which is set as a blood output end , wherein by means of a three-way device , the first plasma separation branch tube is connected to inlet ends of the biological purification branch tube and the non-biological purification branch tube , an outlet end of the non-biological purification branch tube is connected to the biological purification branch tube , and the outlet end of the non-biological purification branch tube is connected to the plasma return branch tube , the three-way device comprises a three-way joint and branches respectively connected to the three-way joint , and at least two said branches are respectively provided with a flow restricting member and a coupling member.2. The combined bio-artificial liver support system as recited in claim 1 , wherein the first plasma separation branch tube comprises: a first plasma separator provided with a blood inlet claim 1 , ...

Подробнее
04-02-2021 дата публикации

SYSTEMS, DEVICES, AND METHODS FOR BODILY FLUID SEPARATION MATERIALS

Номер: US20210031148A1
Принадлежит:

In one embodiment described herein, a bodily fluid separation material is provided comprising a formed component capture region and a bodily fluid pass-through region. The pass-through region has structures with a reduced liquid leaching quality relative to than the capture region, wherein during separation material use, bodily fluid enters the capture region prior to entering the pass-through region. Optionally, a bodily fluid pass-through region has a reduced amount of liquid leaching material relative to than the capture region. 125-. (canceled)26. A filter device comprising: 1) a first capture region formed of a first material and having an anti-hemolytic surface coating over the first material;', '2) a second capture region formed of the first material and without the anti-hemolytic surface coating over the first material; and', '3) a bodily fluid pass-through region formed of the first material and comprising pass-through openings sized so that formed components of the bodily fluid cannot enter said openings in the bodily fluid pass-through region,', 'wherein the second capture region is between the first capture region and the bodily fluid pass-through region., 'a bodily fluid separation material comprising27. The device of wherein at least a portion of the separation material comprises an asymmetric polyethersulfone.28. The device of wherein at least a portion of the separation material comprises polyarylethersulfone.29. The device of wherein at least a portion of the separation material comprises an asymmetric polyarylethersulfone.30. The device of wherein at least a portion of the separation material comprises a polysulfone.31. The device of wherein the separation material comprises an asymmetric polysulfone.32. The device of wherein the anti-hemolytic surface coating comprises single and/or double alkyl chain N-oxides of tertiary amines (NTA).33. A filter device comprising: 1) a first capture region formed of a first material and having an anti-hemolytic ...

Подробнее
05-02-2015 дата публикации

USE OF PLATELET RICH PLASMA COMPOSITION IN THE TREATMENT OF CARDIAC CONDUCTION ABNORMALITIES

Номер: US20150037431A1
Принадлежит:

Methods and kits for treating a cardiac arrhythmia using a platelet rich plasma (PRP) composition are provided. Any type of arrhythmia may be treated using the PRP composition. The PRP composition may comprise PRP developed using blood collected from a patient suffering the cardiac arrhythmia. The PRP composition may be buffered to a physiological pH and may include one or more anti-arrhythmic agents, anti-coagulants, or other drugs. The PRP composition may be delivered using a nebulizer, minimally invasively, or surgically. 1. A method for treating a cardiac conduction abnormality , comprising:identifying a cardiac conduction abnormality in a patient; anddelivering a platelet rich plasma composition to the patient in an amount sufficient to treat the conduction abnormality, wherein delivering the platelet rich plasma composition comprises preparing an inhalable form of the platelet rich plasma composition and providing the inhalable form to the patient.2. The method of claim 1 , wherein the conduction abnormality comprises a cardiac arrhythmia.3. The method of claim 1 , wherein the patient has a negative cardiac enzyme elevation.4. The method of claim 1 , further comprising monitoring the conduction abnormality after delivering the platelet rich plasma composition.5. The method of claim 1 , wherein the conduction abnormality is selected from the group consisting of bradycardia claim 1 , tachycardia claim 1 , ventricular tachycardia claim 1 , and ventricular fibrillation.6. The method of claim 1 , wherein the conduction abnormality is chronic claim 1 , acute or episodic.7. The method of claim 1 , wherein determining a cardiac arrhythmia exists comprises using an electrocardiogram claim 1 , Holter monitor or a cardiac event monitor.8. The method of claim 1 , wherein the platelet rich plasma composition is prepared from whole blood of the patient.9. The method of claim 1 , wherein the platelet rich plasma composition is buffered to a physiological pH claim 1 , and ...

Подробнее
11-02-2016 дата публикации

HEMODIALYSIS SYSTEM HAVING A FLOW PATH WITH A CONTROLLED COMPLIANT VOLUME

Номер: US20160038666A1
Принадлежит: Medtronic, Inc.

Systems and methods for the performance of kidney replacement therapy having or using a dialyzer, control components, sorbent cartridge and fluid reservoirs configured to be of a weight and size suitable to be worn or carried by an individual requiring treatment are disclosed. The system for performing kidney replacement therapy has a controlled compliance dialysis circuit, where a control pump controls the bi-directional movement of fluid across a dialysis membrane. The dialysis circuit and an extracorporeal circuit for circulating blood are in fluid communication through the dialysis membrane. The flux of fluid moving between the extracorporeal circuit and the dialysis circuit is modified by the rate at which the control pump is operating such that a rate of ultrafiltration and convective clearance can be controlled. The system provides for the monitoring of an inlet and outlet conductivity of the sorbent cartridge to provide a facility to quantify or monitor the removal of urea by the sorbent cartridge. 1. A system for performing dialysis , comprising:a microbial filter having an inlet in fluid connection with a dialysis circuit having a sorbent cartridge for removing at least one impurity or waste species from a fluid; andan outlet in fluid connection with a dialyzer having a dialysis membrane.2. The system of claim 1 , wherein the fluid is a dialysate and wherein the dialyzer comprises a blood inlet end for receiving blood claim 1 , a blood outlet end for allowing blood out of the dialyzer claim 1 , a dialysate inlet end for receiving dialysate and a dialysate outlet end for allowing dialysate out of the dialyzer claim 1 , wherein the blood and the dialysate contact different sides of the dialysis membrane.3. The system of claim 2 , wherein the dialysis circuit has one or more conduits for conveying dialysate between the sorbent cartridge and the dialyzer claim 2 , and a dialysate pump for conveying dialysate from the sorbent cartridge claim 2 , to the dialyzer ...

Подробнее
08-02-2018 дата публикации

BLOOD TREATMENT AIR PURGING SYSTEMS

Номер: US20180036472A1
Принадлежит:

Dialysis systems that remove air from a blood circuit are disclosed herein. In an embodiment, a dialysis system includes a dialysis fluid circuit, a blood circuit including an arterial line, a venous line, and an enclosure in fluid communication with the venous line, the enclosure configured to release air through a hydrophobic vent for priming the blood circuit, a blood pump configured to pump fluid through at least the arterial line, a first valve operable with the arterial line and a second valve operable with the venous line, and a pumping and valving algorithm operated after priming to remove air from the blood circuit to control the first and second valves and the blood pump to replace priming fluid with blood from a patient. 1. A dialysis system comprising:a dialysis fluid circuit; an arterial line,', 'a venous line, and', 'an enclosure in fluid communication with the venous line, the enclosure configured to release air through a hydrophobic vent for priming the blood circuit;, 'a blood circuit including'}a blood pump configured to pump fluid through at least the arterial line;a first valve operable with the arterial line and a second valve operable with the venous line; anda pumping and valving algorithm operated after priming to remove air from the blood circuit to control the first and second valves and the blood pump to replace priming fluid with blood from a patient.2. The dialysis system of claim 1 , wherein the enclosure includes an air trap.3. The dialysis system of claim 1 , wherein the hydrophobic vent communicates with the enclosure via a vent line.4. The dialysis system of claim 1 , wherein the priming fluid includes saline claim 1 , heparin or dialysis fluid.5. The dialysis system of claim 1 , wherein the pumping and valving algorithm controls the first and second valves and the blood pump so that the blood from the patient replaces the priming fluid while both the arterial line and the venous line are connected to the patient.6. The dialysis ...

Подробнее
24-02-2022 дата публикации

SYSTEM AND METHOD FOR REMOVAL OF IMMUNE INHIBITORS FROM BIOLOGICAL FLUIDS

Номер: US20220054725A1
Принадлежит:

The present system and method are useful for the removal of immune inhibitors such as soluble TNF receptors from the body fluid of cancer patients. In some embodiments, soluble TNF-Receptors 1 and 2 are selectively removed from plasma at 80% or more efficiency. In some embodiments, the system includes an immobilized capture ligand of a single chain TNFα. The system and method are useful for the treatment of different cancer types, stages and severity. 141-. (canceled)43. The column of claim 42 , wherein the capture efficiency is at least 50%.44. The column of claim 43 , wherein the capture efficiency is at least 80%.45. The column of claim 44 , wherein the capture efficiency is at least 90%.46. The column of claim 45 , wherein the capture efficiency is at least 95%.47. The column of claim 42 , wherein the leaching rate is less than 50 ng/min.48. The column of claim 47 , wherein the leaching rate is less than 10 ng/min.49. The column of claim 42 , wherein:the capture support has a volume;the leaching rate is less than 150 ng/min per ml of capture support.50. The column of claim 49 , wherein the leaching rate is less than 50 ng/min per ml of capture support.51. The column of claim 50 , wherein the leaching rate is less than 10 ng/min per ml of capture support.52. The column of claim 42 , wherein the capture agent comprises a portion of a tumor necrosis factor (TNF).53. The column of claim 52 , wherein the capture agent comprises a single chain TNF.54. The column of claim 53 , wherein the single chain TNF comprises at least three TNF monomers or portions thereof.55. The column of claim 42 , wherein the sTNF-R comprises a TNF-R1.56. The column of claim 42 , wherein the sTNF-R comprises a TNF-R2.57. The column of claim 42 , wherein the capture efficiency and leaching rate are averages over 30 seconds of flow of the plasma through the column.58. The column of claim 42 , wherein the column exhibits the capture efficiency and leaching rate during the first five minutes of ...

Подробнее
24-02-2022 дата публикации

SYSTEM AND METHOD FOR REMOVAL OF IMMUNE INHIBITORS FROM BIOLOGICAL FLUIDS

Номер: US20220054726A1
Принадлежит:

The present system and method are useful for the removal of immune inhibitors such as soluble TNF receptors from the body fluid of cancer patients. In some embodiments, soluble TNF-Receptors 1 and 2 are selectively removed from plasma at 80% or more efficiency. In some embodiments, the system includes an immobilized capture ligand of a single chain TNFα. The system and method are useful for the treatment of different cancer types, stages and severity. 141-. (canceled)43. The column of claim 42 , wherein the leaching rate is less than 50 ng/min.44. The column of claim 43 , wherein the leaching rate is less than 10 ng/min.45. The column of claim 42 , wherein:the capture support has a volume;the leaching rate is less than 150 ng/min per ml of capture support.46. The column of claim 45 , wherein the leaching rate is less than 50 ng/min per ml of capture support.47. The column of claim 46 , wherein the leaching rate is less than 10 ng/min per ml of capture support.48. The column of claim 42 , wherein the capture agent comprises a portion of a tumor necrosis factor (TNF).49. The column of claim 48 , wherein the capture agent comprises a single chain TNF.50. The column of claim 49 , wherein the single chain TNF comprises at least three TNF monomers or portions thereof.51. The column of claim 42 , wherein the sTNF-R comprises a TNF-R1.52. The column of claim 42 , wherein the sTNF-R comprises a TNF-R2.53. The column of claim 42 , wherein the leaching rate is an average over 30 seconds of flow of the plasma through the column.54. The column of claim 42 , wherein the column exhibits the leaching rate during the first five minutes of flow.55. The column of claim 42 , wherein the leaching rate is an average over 2 hours of flow of the plasma through the column.56. The column of claim 42 , wherein the column exhibits the leaching rate at any time during flow of the plasma through the column. The present disclosure pertains to a system and method for removal of immune inhibitors ...

Подробнее
24-02-2022 дата публикации

SYSTEM AND METHOD FOR REMOVAL OF IMMUNE INHIBITORS FROM BIOLOGICAL FLUIDS

Номер: US20220054727A1
Принадлежит:

The present system and method are useful for the removal of immune inhibitors such as soluble TNF receptors from the body fluid of cancer patients. In some embodiments, soluble TNF-Receptors 1 and 2 are selectively removed from plasma at 80% or more efficiency. In some embodiments, the system includes an immobilized capture ligand of a single chain TNFα. The system and method are useful for the treatment of different cancer types, stages and severity. 141-. (canceled)42. A system for removing a target component from a body fluid of a patient , the system comprising:a housing;an inlet coupled to the housing and configured to receive the body fluid;a plurality of sequestering chambers disposed within the housing and configured to each receive a portion of the body fluid from the inlet; andan access port coupled to the housing and configured to facilitate insertion and/or removal of a capture support to or from one of the plurality of sequestering chambers.43. The system of claim 42 , wherein the access port comprises a plurality of access ports respectively configured to facilitate insertion and/or removal of one of a plurality of capture supports to or from one of the plurality of sequestering chambers.44. The system of claim 42 , wherein the plurality of sequesting chambers are arranged in parallel claim 42 , with each sequesting chamber coupled independently to the inlet.45. The system of claim 42 , wherein:the plurality of sequesting chambers are arranged in series;a first sequesting chamber is coupled to the inlet and configured to receive all of the body fluid from the inlet; andthe first sequesting chamber is coupled to a second sequesting chamber such that all of the body fluid passes from the first sequesting chamber to the second sequestering chamber.46. The system of claim 45 , wherein the second sequesting chamber is coupled directly to the outlet such that all of the body fluid passes from the second sequestering chamber to the outlet.47. The system of ...

Подробнее
24-02-2022 дата публикации

SYSTEM AND METHOD FOR REMOVAL OF IMMUNE INHIBITORS FROM BIOLOGICAL FLUIDS

Номер: US20220054728A1
Принадлежит:

The present system and method are useful for the removal of immune inhibitors such as soluble TNF receptors from the body fluid of cancer patients. In some embodiments, soluble TNF-Receptors 1 and 2 are selectively removed from plasma at 80% or more efficiency. In some embodiments, the system includes an immobilized capture ligand of a single chain TNFα. The system and method are useful for the treatment of different cancer types, stages and severity. 141-. (canceled)42. A system for removing a target component from a body fluid of a patient , the system comprising:a housing;an inlet coupled to the housing and configured to receive the body fluid;a plurality of sequestering chambers disposed within the housing; anda plurality of flow control valves respectively coupled between the inlet and one of the plurality of chambers.43. The system of claim 42 , wherein each flow control valve is coupled directly to the inlet.44. The system of claim 42 , wherein:each of the plurality of flow control valves can independently be open or closed;an open flow control valve enables a portion of the body fluid to flow into the respective one of the plurality of chambers; anda closed flow control valve prevents the body fluid from flowing into the respective one of the plurality of chambers.45. The system of claim 42 , further comprising an outlet coupled to the housing and configured to receive the body fluid from the plurality of chambers.46. The system of claim 45 , further comprising a plurality of filters disposed within the housing so as to separate the plurality of chambers from the inlet and the outlet.47. The system of claim 42 , further comprising a capture support disposed within one of the plurality of chambers and configured to bind to a target component.48. The system of claim 47 , wherein the capture support comprises a plurality of capture supports respectively disposed within the plurality of chambers and respectively configured to bind to one of a plurality of target ...

Подробнее
03-03-2022 дата публикации

Aspiration Syringes and Methods Thereof

Номер: US20220062528A1
Принадлежит:

Aspiration syringes and methods thereof are disclosed. An exemplary aspiration syringe can include a barrel, a plunger disposed in the barrel, and an aspiration mechanism. The aspiration mechanism can include a thumb-support member coupled to a distal portion of the barrel and a syringe housing slidably disposed around the barrel. The syringe housing can include a proximal portion coupled to a proximal portion of the plunger and a distal portion terminating with a flange incorporated into a finger-support member. The aspiration mechanism can be configured for withdrawing the plunger from the barrel as the finger-support member is slid over the barrel toward the thumb-support member. An example method of the foregoing aspiration syringe can include a fluid-aspirating step including aspirating fluid from a fluid-containing space with a single hand over a medial portion of the syringe by squeezing together the finger-support member and the thumb-support member.

Подробнее
14-02-2019 дата публикации

Blood Treatment With Inactivation Of Circulating Nucleic Acids

Номер: US20190046717A1
Принадлежит: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH

The present invention relates to a device for the treatment of blood comprising a solid phase on which a polypeptide is immobilized which is suitable for the inactivation of free nucleic acids. Suitable polypeptides are, for example, deoxyribonucleases, ribonucleases, DNA methyltransferases or cytosine deaminases. The invention further comprises the use of such devices for the treatment of patients suffering from chronic kidney failure, cancer or lupus erythematosus, as well as methods and systems for the treatment of blood, wherein free nucleic acids are inactivated outside the body. 1. A device for the treatment of blood , comprising(a) tubes for whole blood or blood plasma to flow through from and to the patient,(b) a solid phase on which a polypeptide is immobilized which is suitable for the inactivation of free nucleic acids.2. The device according to claim 1 , wherein the device furthermore comprises (c) a dialyzer or haemofilter.3. The device according to claim 1 , wherein the polypeptide is selected from the group consisting of deoxyribonucleases claim 1 , ribonucleases claim 1 , endonucleases claim 1 , exonucleases claim 1 , endoribonucleases claim 1 , exoribonucleases or peptides with nuclease activity.4. The device according to claim 1 , wherein the polypeptide is selected from the group consisting of DNA methyltransferases 1 (DNMT1) or peptides with methyltransferase activity.5. The device according to claim 1 , wherein the polypeptide has a cytosine deaminase activity.6. The device according to claim 2 , wherein the solid phase is upstream of the dialyzer or haemofilter.7. The device according to claim 2 , wherein the solid phase is located within the dialyzer or haemofilter.8. The device according to claim 1 , wherein the device furthermore comprises (d) a plasma filter.9. The device according to claim 1 , wherein the solid phase on which the polypeptide is immobilized comprises a hollow fibre membrane claim 1 , beads or a non-woven.10. The device ...

Подробнее
25-02-2016 дата публикации

MEDICAL SOLUTION AUTHENTICATION

Номер: US20160051746A1
Принадлежит:

A system of authenticating a medical solution used in a blood processing procedure, comprising a blood processing system having a user interface and access to a database of medical solutions identifiable by identifiers, wherein the blood processing system guides a user through steps of the procedure and the user interface prompts the user to execute an action as part of a step; a fluid circuit having an inlet for a medical solution, wherein the fluid circuit is coupled to the fluid processing system; wherein a step of the blood processing procedure comprises drawing a solution into the circuit, wherein the interface receives a user input of an identifier of the solution prior to the fluid processing system executing the step; wherein the fluid processing system is configured to compare the received identifier to medical solution identifiers within the database and, based on a result of the comparison, executing the step. 1. A blood processing system , comprising:a blood processing device having a user interface and a memory;a database of medical solutions identifiable by identifiers;a fluid circuit for use with the blood processing device having an inlet for a medical solution;wherein the blood processing device is configured to guide a user through one or more steps of a blood processing procedure including prompting a user to input an identifier of a medical solution, compare the identifier to information within the database, and authorize use of the medical solution upon verification of the identifier within the database.2. The system of claim 1 , wherein the fluid processing system is configured to alert the user via the user interface in the event that the medical solution is not an approved solution.3. The system of claim 1 , wherein the medical solution comprises at least one of an infusion solution claim 1 , blood additive solution claim 1 , anticoagulant solution claim 1 , saline solution claim 1 , blood component solution claim 1 , and replacement fluid.4. ...

Подробнее
25-02-2021 дата публикации

POLYMERS FOR REVERSING HEPARIN-BASED ANTICOAGULATION

Номер: US20210052635A1
Принадлежит: University of British Columbia

Embodiments presented herein relate to various polymers. Some of the polymer embodiments are heparin binding polymers. Some embodiments of the heparin binding polymers can be employed to bind to heparin for methods such as separating, purifying, removing, and/or isolating heparin and heparin like molecules. 1 {'sub': '1-18', 'sup': '1', 'claim-text': {'sup': '1', 'wherein each Ris independently selected from a polymer segment having monomer units of Formula (III), 'a core unit, wherein the core unit comprises a Calkyl substituted with three or more of —OR,'}, 'administering a heparin binding polymer to the subject, wherein the heparin binding polymer comprises. A method of counteracting heparin in a subject, the method comprising: wherein n is an integer from 1 to 10,000,', {'sup': 2', '1, 'wherein each Ris independently selected from a hydrogen, carbon, a cationic moiety, R, and a polymer segment of Formula (IV)]}}} [{'sup': '3', 'wherein each Ris independently selected from an oxygen cationic moiety, a hydroxyl, and a polymer segment of Formula (IV),'}, 'wherein m is an integer from 1 to 10,000,', {'sup': '4', 'sub': '1-6', 'wherein each Ris independently selected from a Calkoxy, and'}]}}}wherein the heparin binding polymer comprises 1 to 300 cationic moieties. This application is a continuation under 35 U.S.C. § 120 of U.S. application Ser. No. 15/887,561, filed Feb. 2, 2018, which is a continuation under 35 U.S.C. § 120 of U.S. application Ser. No. 14/629,408, filed on Feb. 23, 2015, now U.S. Pat. No. 10,111,902, which is a continuation under 35 U.S.C. § 120 of U.S. application Ser. No. 14/098,184, filed on Dec. 5, 2013, now U.S. Pat. No. 9,095,666, which is a divisional under 35 U.S.C. § 121 of U.S. application Ser. No. 13/458,899, filed on Apr. 27, 2012, now U.S. Pat. No. 8,637,008, which is a continuation under 35 U.S.C. § 120 of U.S. application Ser. No. 13/504,841, filed on Apr. 27, 2012, now U.S. Pat. No. 8,519,189, which was the U.S. National Phase entry ...

Подробнее
23-02-2017 дата публикации

Systems And Methods For Ensuring Proper Tubing Installation For Fluid Processing Systems

Номер: US20170052124A1
Принадлежит:

A fluid separation system is provided for separating a plasma-containing fluid into separated plasma and a concentrated fluid. The system cooperates with a fluid flow circuit including a fluid separation chamber and a plasma outlet line associated therewith for removing separated plasma from the fluid separation chamber. The system includes an optical sensor assembly that receives a portion of the plasma outlet line when the fluid flow circuit has been associated with the fluid separation system. To ensure proper installation of the plasma outlet line, the optical sensor assembly compares light received by its light detector to a baseline value, which is indicative of the amount of light received by the light detector before the plasma outlet line has been installed. The amount of received light being equal to or less than a selected percentage of the baseline value indicates that the plasma outlet line has been properly installed. 1. A fluid processing system configured to cooperate with a fluid flow circuit , the fluid processing system comprising: a light source configured to emit a light, and', 'a light detector configured to receive a portion of the light emitted by the light source and to produce an output indicative of the amount of received light; and, 'an optical sensor assembly configured to receive a portion of the fluid flow circuit and comprising'} comparing the output from the light detector to a baseline value that is indicative of the amount of light from the light source that is received by the light detector in the absence of said portion of the fluid flow circuit, and', 'determining that said portion of the fluid flow circuit is properly received by the optical sensor assembly if the output from the light detector is equal to or less than a selected percentage of the baseline value., 'a controller configured to receive the output from the light detector and programmed to determine whether said portion of the fluid flow circuit is properly received ...

Подробнее
10-03-2022 дата публикации

TREATMENT OF VIRAL INFECTION BY APHERESIS

Номер: US20220072210A1
Автор: ELIAZ ISAAC
Принадлежит: ELIAZ THERAPEUTICS, INC.

The invention is directed to the treatment of COVID-19 patients by withdrawing SARS-CoV-2 viral particles from the patient's circulation by apheresis using a binding agent in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles. The reduction in viral particles may be combined by reduction of active gal-3 levels in the patient which may provide further relief of conditions associated with COVID-19 that may include symptoms associated with the cytokine storm that is associated with COVID-19 infection. Both SARS-CoV-2 viral particles and gal-3 may be bound by modified citrus pectin of less than sixty thousand Daltons. The process may be combined with the administration of supportive agents like antivirals, anti-inflammatories, immune based inhibitors, vitamins and modified citrus pectin. 1. A method of treating a patient suffering from COVID-19 , comprising: conducting apheresis on the blood of said patient to reduce circulating levels of SARS-CoV-2 viral particles , wherein said apheresis comprises intimately contacting the viral particles in said blood with an agent that binds said viral particles , selectively withdrawing the bound viral particles from said blood , and returning said blood to said patient thereafter.2. The method of wherein said agent is modified citrus pectin of less sixty thousand Daltons molecular weight claim 1 , an antibody which specifically binds to said viral particles claim 1 , an antibody fragment which specifically binds to said viral particles claim 1 , and mixtures thereof.3. The method of claim 1 , wherein said apheresis is conducted using the whole blood of said patient.4. The method of claim 1 , wherein the blood of said patient is treated to remove blood cells therefrom claim 1 , creating a plasma which is then subjected to said apheresis claim 1 , and wherein said blood cells are returned with said treated plasma to said patient.5. The method of claim 1 , wherein said apheresis ...

Подробнее
22-05-2014 дата публикации

Systems, devices and methods for resuscitation

Номер: US20140142548A1
Принадлежит: Individual

Methods, devices, systems of resuscitating a patient including accessing an arterial vessel positioning a catheter into the arterial vessel advancing the catheter through the arterial vessel to position it below a vessel supplying blood to a heart and a brain expanding an expandable portion of the catheter to prevent blood from flowing past the expanded portion and infusing a substance retrograde into the artery within the arterial section between the heart and the expanded portion of the catheter.

Подробнее
10-03-2016 дата публикации

LIGANDS AND METHODS FOR ISOLATING OR REMOVING PROTEINS

Номер: US20160067674A1
Принадлежит:

The present disclosure relates generally to sorbents for binding proteins from blood plasma comprising a solid carrier material and an oligopeptide immobilized thereon, which selectively binds the protein from the blood plasma, and to a method for separating autologous proteins from blood plasma wherein the blood plasma is brought in contact with a corresponding sorbent, the desired protein is allowed to bind to the sorbent, the sorbent is separated from the plasma and the protein is subsequently separated from the sorbent. Corresponding sorbents and method allows for the selective isolation of specific blood plasma proteins directly from the blood plasma without having to conduct a tedious fractionation. This significantly improves the protein yield and provides a highly effective isolation of blood plasma protein constituents such as IgG, albumin, factor V and factor VIII in a simple, cheap and time-efficient process. 1. Sorbent for binding proteins from blood plasma , comprising a solid carrier material and an oligopeptide immobilized thereon , which selectively binds a protein from the blood plasma.2. Sorbent according to claim 1 , wherein the oligopeptide has 8 to 50 claim 1 , preferably 10 to 30 and in particular 12 to 20 amino acids.3. Sorbent according to claim 1 , wherein the oligopeptide selectively binds to IgG claim 1 , factor V claim 1 , factor VIII or albumin.6. Sorbent according to claim 1 , wherein the solid carrier material is a latex claim 1 , preferably a magnetic latex.7. Container having an inlet and an outlet for fluids which comprises a filling of a sorbent according to .8. Container according to claim 7 , wherein the outlet is positioned on the side opposite to the inlet on the container.10. Use of the oligopeptide of for the detection of the presence or absence of IgG claim 9 , in particular specific IgG claim 9 , factor V or factor VIII in an analyte.11. Method for separating a blood plasma protein from blood plasma claim 9 , supernatants ...

Подробнее
29-05-2014 дата публикации

Blood processing filter and the method for manufacturing the same

Номер: US20140144832A1
Принадлежит: Asahi Kasei Medical Co Ltd

This invention relates to a blood processing filter comprising a sheet-like filter element, an inlet-side flexible container and an outlet-side flexible container that sandwich the filter element and are sealed thereto, an inlet port provided in the inlet-side flexible container for accepting blood before being processed by the filter element, and an outlet port provided in the outlet-side flexible container for discharging blood after being processed by the filter element. The blood processing filter also includes a flow channel securing sheet arranged between the filter element and the outlet-side flexible container. A flow channel hole through which blood processed by the filter element passes is formed in the flow channel securing sheet. The outlet port is provided so as to be capable of communicating with the flow channel hole.

Подробнее
09-03-2017 дата публикации

Dialysis systems including therapy prescription entries

Номер: US20170065761A1

A dialysis system includes a dialysis machine configured to control fluid loss or ultrafiltration (“UF”) volume over a treatment; a graphical user interface (“GUI”) that allows selection of a prescription entry for the treatment; and a processor operating with the GUI, the processor programmed to (i) receive a plurality of prescription entries via a local or wide area mode of data communication, each prescription entry including at least one prescribed parameter for operating the dialysis machine to control the fluid loss or UF volume, and (ii) enable an operator to choose between the prescription entries provided at the GUI, and select one of the prescription entries for the treatment.

Подробнее
11-03-2021 дата публикации

SYSTEMS AND METHODS FOR TREATING BLOOD

Номер: US20210069402A1
Принадлежит: Humanity Life Extension LLC.

According to some embodiments, a system may treat blood outside the body of a patient. The system may include one or more pumps configured to pump blood in a fluid flow path at a collective rate over 5 liters per minute. The system may include one or more heat exchangers operable to heat at least a portion of the blood to a temperature of at least 42 degrees Celsius and to allow the blood to cool one or more degrees following heating. The system may include one or more convection dialysis modules configured to perform convection dialysis on at least a portion of the blood at least after the one or more heat exchangers allow the blood to cool one or more degrees. 174-. (canceled)75. A method for treating cancer , comprising:heating a human body to a core temperature between 42 and 43.2 degrees Celsius, wherein blood from the human body is flowing outside of the human body in a fluid flow path; andremoving carbon dioxide from at least a portion of the blood flowing in the fluid flow path.76. The method of claim 75 , further comprising adding oxygen to at least a portion of the blood.77. The method of claim 75 , wherein carbon dioxide is removed from at least a portion of the blood by causing at least a portion of the blood to flow through at least one membrane.78. The method of claim 77 , wherein the at least one membrane collectively has an effective surface area greater than 1.8 square meters.79. The method of claim 75 , further comprising causing the production of reactive oxygen species within the human body by adding a substance to at least a portion of the blood outside of the human body.80. The method of claim 75 , further comprising performing convection dialysis on at least a portion of the blood at a rate between 0.5 and 1.8 liters per minute.81. The method of claim 75 , further comprising pumping blood from the human body into the fluid flow path at a rate between 4 and 7 liters per minute.82. The method of claim 75 , wherein the blood is pumped in the ...

Подробнее
12-03-2015 дата публикации

Tip Configurations for Multi-Lumen Catheter

Номер: US20150073327A1
Принадлежит:

Multi-lumen catheters with improved tip configurations, including a triple-lumen catheter which may be useful for apheresis. In one variation, the catheter has three lumens with distal openings angularly spaced apart and staggered axially with respect to one another. In another variation, the catheter has two lumens exiting distally and one centrally positioned lumen exiting proximally. A third variation is a catheter with a single distal opening and two proximal openings. The staggered lumen openings along the axial length of the catheter may decrease recirculation while maximizing flow rates. 1. A multi-lumen catheter , comprising:a first interior wall separating a first lumen from a second lumen;a second interior wall separating the first lumen from a third lumen, the second interior wall and the first interior wall meeting at a central axis of the catheter;a third interior wall separating the second lumen from the third lumen;a first distal opening in fluid communication with the first lumen;a second distal opening in fluid communication with the second lumen; anda third distal opening in fluid communication with the third lumen, the third distal opening positioned proximal of the second distal opening, the second distal opening positioned proximal of the first distal opening.2. The multi-lumen catheter according to claim 1 , wherein the second interior wall and the first interior wall form an angle of approximately 120 degrees.3. The multi-lumen catheter according to claim 1 , wherein each of the first claim 1 , second claim 1 , and third lumens has a constant cross-section from a proximal end of the catheter to a distal end thereof.4. The multi-lumen catheter according to claim 3 , wherein each of the first claim 3 , second claim 3 , and third lumens has a similar cross-sectional shape.5. The multi-lumen catheter according to claim 1 , wherein the first lumen increases in cross-sectional area from the second lumen to a distal end of the catheter.6. The multi- ...

Подробнее
19-03-2015 дата публикации

Hemodialysis system including a disposable cassette

Номер: US20150076044A1

A dialysis system includes a dialyzer, a sorbent cartridge configured to clean used dialysate from the dialyzer, a dialysate pump actuator configured to pump dialysate to the dialyzer, and a conductivity sensor located adjacent to a temperature sensor. The dialysis system also includes a disposable cassette configured to carry dialysate pumped by the dialysate pump actuator. The disposable cassette includes a combined conductivity and temperature sensor fluid chamber separate from the conductivity sensor and the temperature sensor and located so as to operate with the conductivity sensor and the temperature sensor, respectively, when mounted for operation.

Подробнее
19-03-2015 дата публикации

Systems, devices, and methods for bodily fluid separation materials

Номер: US20150076054A1
Принадлежит: Theranos Inc

In one embodiment described herein, a bodily fluid separation material is provided comprising a formed component capture region and a bodily fluid pass-through region. The pass-through region has structures with a reduced liquid leaching quality relative to than the capture region, wherein during separation material use, bodily fluid enters the capture region prior to entering the pass-through region. Optionally, a bodily fluid pass-through region has a reduced amount of liquid leaching material relative to than the capture region.

Подробнее
16-03-2017 дата публикации

Integrated Leukocyte, Oxygen and/or CO2 Depletion, and Plasma Separation Filter Device

Номер: US20170072339A1
Принадлежит: NEW HEALTH SCIENCES, INC.

A blood filter device comprising: a housing comprising an outer wall and a first inlet, a first outlet and a second outlet; a membrane which is capable of separating plasma from the blood, wherein the membrane forms an inner chamber; a leukocyte and oxygen and/or carbon dioxide depletion media disposed wherein the inner chamber, the leukocyte and oxygen and/or carbon dioxide depletion media is capable of depleting leukocytes and oxygen and/or carbon dioxide from the blood; an outer chamber disposed between the outer wall and the membrane, wherein the plasma which permeates through the membrane enters the outer chamber and exits the filter device via the first outlet; whereby the blood which has been depleted of oxygen and/or carbon dioxide, leukocytes and plasma exists and filter device via the second outlet. 138.-. (canceled)39. A method for processing blood , comprising: a housing comprising an outer wall, a first inlet, a first outlet and a second outlet;', 'a membrane which is capable of separating plasma from said blood, wherein said membrane forms at least one inner chamber within said housing and said blood enters said at least one inner chamber of said blood filter device through said first inlet;', 'a leukocyte, carbon dioxide, and oxygen depletion media disposed within said at least one inner chamber, said leukocyte, carbon dioxide, and oxygen depletion media is capable of depleting leukocytes, carbon dioxide and oxygen from said blood; and', 'an outer chamber disposed between said outer wall and said membrane,, 'passing said blood through a blood filter device comprisingseparating said plasma from said blood by permeating through said membrane, wherein said plasma enters said outer chamber and exits said housing via said first outlet; anddepleting oxygen, leukocytes and plasma from said blood, whereby oxygen, leukocytes and plasma depleted blood exits said housing via said second outlet as packed red blood cells (pRBCs).40. The method according to claim ...

Подробнее
18-03-2021 дата публикации

SYSTEM AND METHOD FOR CONNECTING A CONCENTRATE CONTAINER WITH A BLOOD TREATMENT DEVICE WITHOUT LEAKAGES

Номер: US20210077697A1
Принадлежит: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH

The present invention refers to a container comprising a connection portion allowing for an easy, efficient and more hygienic connection of the container to a fluid dosing unit of a blood treatment device. According to the present invention the fluid dosing unit comprises a valve that fluidically closes the fluid dosing unit if no container is connected to the fluid dosing unit and that opens the fluid dosing unit upon connection of a container to the fluid dosing unit. Thus, undesired spillages potentially arising upon disconnection of the container from the fluid dosing unit can be avoided. 1. Container for concentrate , comprising:a main body for containing concentrate,a connection portion having a flat end surface facing away from the main body and an opening through that the main body can be filled with concentrate,a inlet through that fluid can be supplied to the main body and an outlet through that fluid can be withdrawn from the main body, wherein at least in the outlet a fluid permeable actor is arranged that is configured to open a valve in a fluid line of a fluid dosing unit when the container is connected to the fluid dosing unit to fluidically couple the container to the fluid dosing unit.2. Container according to claim 1 , wherein the fluid permeable actor comprises a spike configured to open the valve and at least one lumen to conduct fluid.3. Container according to claim 1 , wherein the outlet and the inlet each project along a straight line traversing the connection portion from the flat end surface facing away from the main body to a flat end surface facing the main body.4. Container according to claim 1 , wherein the container comprises two attachment elements arranged at two opposing sides of the connection portion and configured to reversibly attach the container to two corresponding attachment elements present on a blood treatment device claim 1 , whereinthe two attachment elements project in a first direction and the outlet and inlet project ...

Подробнее
18-03-2021 дата публикации

SYSTEM AND METHOD FOR OPENING A CONCENTRATE CONTAINER AND CONNECTING THE CONCENTRATE CONTAINER TO A BLOOD TREATMENT DEVICE

Номер: US20210077698A1
Принадлежит: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH

The present invention refers to a system and method for opening a concentrate container without the need for a human to directly handle the concentrate container and connecting the concentrate container to a blood treatment device. Aspects of the invention are directed to a container for concentrate and a blood treatment device. 1. Container for concentrate , comprising:a main body for containing concentrate,a connection portion having a flat end surface and configured to connect the container to a blood treatment device,two attachment elements arranged at two opposing sides of the connection portion and configured to reversibly attach the container to two corresponding attachment elements present on a blood treatment device, andtwo connection elements each comprising an opening at the fiat end surface of the connection portion and configured to interact with two corresponding connection elements present on a blood treatment device to fluidically couple the container with the blood treatment device by insertion of the connection elements present on the blood treatment device into the connection elements of the container, andat least one opening element configured to interact with a blood treatment device to remove a lid from the container.2. Container according to claim 1 , wherein the at least one opening element configured to interact with a blood treatment device to remove a lid from the container has the form of a lever preferably made of a stiff material that is arranged between the lid and the flat end surface of the connection portion and is movable relative to the flat end surface claim 1 , preferably in a direction away from the flat end surface.3. Container according to claim 2 , wherein the lever comprises a curved section preferably at a front edge of the lever and the curved section is preferably curved away from the flat end surface of the connection portion claim 2 ,4. Container according to claim 1 , wherein the at least one opening element ...

Подробнее
18-03-2021 дата публикации

SYSTEM AND METHOD FOR CONNECTING A CONCENTRATE CONTAINER WITH A BLOOD TREATMENT DEVICE

Номер: US20210077699A1
Принадлежит: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH

The present invention refers to a system and method for connecting a concentrate container with a blood treatment device with improved hygiene. Furthermore, the invention refers to a container and blood treatment device to be used in a method according to the present invention. 1. Container for concentrate , comprising:a main body for containing concentrate,a connection portion having a flat end surface and configured to connect the container to a blood treatment device,two attachment elements arranged at two opposing sides of the connection portion and configured to reversibly attach the container to two corresponding attachment elements present on a blood treatment device, andtwo connection elements each comprising an opening at the flat end surface of the connection portion and configured to interact with two corresponding connection elements present on a blood treatment device to fluidically couple the container with the blood treatment device by insertion of the connection elements present on the blood treatment device into the connection elements of the container, whereinthe two attachment elements project in a first direction and the two connection elements project in a second direction that is oriented essentially at right angles to the first direction.2. Container according to claim 1 , wherein the second direction in that the two connection elements project is oriented essentially in parallel to the longitudinal axis of the main body of the container and the two connection elements each have the form of a hollow cylinder opened at the flat end surface of the connection portion.3. Container according to claim 1 , wherein the attachment elements are each formed as a hook or as a hollow cylinder.4. Container according to claim 1 , wherein the two connection elements are sealed by a lid in the form of a flexible film removably attached to the flat end surface of the connection portion and wherein the flexible film can be peeled off the flat end surface of the ...

Подробнее
26-03-2015 дата публикации

Portable Dialysis Cabinet

Номер: US20150083647A1
Принадлежит: Medtronic, Inc.

A portable dialysis cabinet for use in dialysis. The portable dialysis cabinet can have a size and weight that facilitates easy movement of the cabinet from one location to another with relative ease. The portable dialysis cabinet can have additional features necessary to facilitate portability, such as wheels and a handle. In general, the portable dialysis cabinet can contain all the necessary components for performing a dialysis session. 1. A portable dialysis cabinet , comprising:a dialysis system; andat least two wheels disposed on a bottom surface of the dialysis cabinet.2. The portable dialysis cabinet of claim 1 , further comprising at least four wheels.3. The portable dialysis cabinet of claim 1 , wherein one or more wheels of the portable dialysis cabinet is detachable.4. The portable dialysis cabinet of claim 1 , further comprising a handle disposed on the exterior portion of the dialysis cabinet.5. The portable dialysis cabinet of claim 4 , wherein the handle is a telescoping handle.6. The portable dialysis cabinet of claim 1 , further comprising at least one door hingeably disposed on the dialysis cabinet creating an interior portion of the dialysis cabinet and an exterior portion of the dialysis cabinet.7. The portable dialysis cabinet of claim 6 , wherein the at least one door comprises at least one shelf claim 6 , and the dialysis cabinet further comprises a user interface module attached to the dialysis cabinet and in electronic communication with a control module.8. The portable dialysis cabinet of claim 7 , wherein the user interface comprises one or more of a keyboard claim 7 , a touch screen claim 7 , a display screen claim 7 , a mouse claim 7 , a microphone claim 7 , and a speaker.9. The portable dialysis cabinet of claim 7 , wherein the user interface is a stowable user interface claim 7 , and wherein the dialysis cabinet comprises a recess into which the user interface can be stowed.10. The portable dialysis cabinet of claim 1 , further ...

Подробнее
26-03-2015 дата публикации

HIGH CITRATE DIALYSATE AND USES THEREOF

Номер: US20150083664A1
Принадлежит:

The dose of dialysis in terms of urea clearance is marginal in many hemodialysis patients, and metabolic acidosis as determined by the pre-dialysis serum HCOlevel is common. A dialysate that included citric acid rather than acetic acid as acidifying agent provides superior performance properties. Citrate-containing dialysate was used exclusively in 22 hemodialysis patients. Initially, only 8 of the 22 patients had a pre-dialysis serum HCO>23 mEq/L (lower limit of normal), however, after 12 weeks of dialysis using the citrate-containing dialysate, the serum HCOnormalized in 15 patients (p=0.0001, Chi-square). Dialysis variables were kept constant in 19 of the patients, who also used and reused the same dialyzer model throughout. In these patients, the initial average urea reduction ratio (URR) was 68.5±5.9%, and after treatment with the citrate dialysate disclosed herein, this ratio had increased to 73±5.3% (p<0.03). SpKt/V, calculated using the Daugirdas II formula, also increased from 1.23±0.19 to 1.34±0.2 (p=0.01). This increased urea clearance may be the result of the anticoagulant property of citrate maintaining patency of the dialyzer membrane. The increase in pre-dialysis serum HCOmay represent increased delivery from the dialysate and production from citric acid. 131-. (canceled)32. A method of performing dialysis on a patient in need thereof , wherein the method comprises:a) performing the dialysis wherein the patient is heparin-free during the time of dialysis; andb) performing the dialysis in a dialyzer with a dialysate composition comprising citrate at a concentration ranging from 2.4 to 20 mEq/L, calcium at a concentration ranging from 2.5 to 5 mEq/L and magnesium at a concentration ranging from 0.75 to 2 mEq/L, wherein the patient has an intolerance to heparin, an antibody to heparin, a risk of bleeding from the use of direct administration of heparin or chronic acidosis.33. The method of wherein the dialysis results in an increased urea transfer from ...

Подробнее
25-03-2021 дата публикации

PLATELET RICH PLASMA SEPARATION KIT

Номер: US20210085841A1
Принадлежит: Enso Discoveries, LLC

The present invention discloses a sterile PRP separation kit that has compartmentalized container having a cover that allows for a stage-specific exposure of sterile components of the sterile PRP separation kit housed within stage-specific compartments to a non-sterile environment commensurate with a specific stage of operation of a separation process of PRP. The sterile PRP separation kit includes a PRP tube with segregated portals for injection of blood into the PRP tube, aspiration of PRP from the PRP tube, and for maintaining an interior pressure of the PRP tube at equilibrium with ambient pressure during both injection and aspiration. 1. A sterile platelet rich plasma (PRP) separation kit , comprising:a compartmentalized container having a cover that allows for a stage-specific exposure of sterile components of the sterile PRP separation kit housed within stage-specific compartments to a non-sterile environment commensurate with a specific stage of operation of a separation process of PRP, having:a first stage that includes a first set of sterile components housed within a first set of compartments and exposed only for aseptic collection of blood;with the first set of sterile components, comprising:a first stage syringe;a first stage needle; anda winged infusion set;a second stage that includes a second set of sterile components housed within a second set of compartments and exposed only for filling in a PRP tube with aseptically collected blood from the first stage;with the second set of sterile components, comprising:the PRP tube; anda second stage needle that is connected to the first stage syringe for injecting the aseptically collected blood into the PRP tube for separation of PRP;a third stage that includes a third set of sterile components housed within a third set of compartments and exposed only for aspirating the PRP from the PRP tubes of the second stage;with the third set of sterile components, comprising:a lateral aspiration spinal needle;a third ...

Подробнее
21-03-2019 дата публикации

PURIFIED BLOOD FOR USE IN CANCER THERAPY

Номер: US20190083531A1
Принадлежит: Bavarian Immunology Association GmbH

The present invention is generally in the field of enhancing an immune response. Particularly, it relates to purified blood for use in a method of treating cancer in a patient by extracorporeally removing inhibitors of immune mediators. 1. A method of treating cancer in a patient , the method comprising a blood purification process comprisinga) including an extracorporeal circuit comprising a blood-fractionating device having a plasma-separation element and an immune adsorption element into the patient's blood circle; (i) blood is continuously taken from the patient;', {'sup': '3', '(ii) the blood is separated into blood plasma and remainder, wherein blood is passed through the plasma-separation element with a flow rate of at least 300 cm/min;'}, "(iii) the blood plasma is purified from soluble TNF receptor-1 (sTNF-R1) and soluble TNF receptor-2 (sTNF-2) in the immune adsorption element, wherein a plasma volume corresponding to at least 20% of the patient's weight is passed through the immune adsorption element per day;", '(iv) blood is restored by combining the purified blood plasma and the remainder; and', '(v) the restored blood is continuously returned into the patient; and, "b) passing the patient's blood through the extracorporeal circuit, wherein"}c) separating the extracorporeal circuit from the patient's blood circle,wherein the blood purification process is performed on at least six days within a period of at most four weeks.2. The method of claim 1 , wherein the blood purification process is performed once claim 1 , twice claim 1 , three times or four times a day claim 1 , until the intended daily plasma volume has been purified by passing it through the immune adsorption element.3. The method of claim 1 , wherein the blood purification process is performed on at least 6 days within a period of at most 15 days.4. The method of claim 1 , wherein the method is continued for at least one month.5. The method of claim 1 , wherein a plasma volume corresponding ...

Подробнее
21-03-2019 дата публикации

FORMULATION, APPARATUS, AND METHODS FOR TREATMENT OF BRAIN TRAUMA

Номер: US20190083532A1
Автор: Hughes John C.
Принадлежит:

A formulation comprising platelet rich plasma (PRP) for treatment of patients who have experienced brain injury, consisting of: a mixture of human plasma composed of pluripotent adult stem cells comprising very small embryonic like stem cells from autologous plasma or allogeneic plasma, D5W, glutathione, methylcobalamin, and regular insulin. The formulation is infused directly adjacent to a patient's brain through the nostrils or nares of the nasal cavity. Treatment using the formulation may be supplemented with one or more therapies including hyperbaric oxygen therapy (HBOT), cranial osteopathic therapy, intravenous (IV) nutrition, electroencephalographic (EEG) biofeedback, low level laser therapy (LLLT), transcranial magnetic stimulation (TMS), additional PRP pluripotent adult stem cell treatments, and a ketogenic diet and medium-chain triglyceride (MCT) oil therapy. 1. A formulation comprising platelet rich plasma (PRP) for treatment of patients who have experienced brain injury , consisting of: a mixture of human plasma composed of pluripotent adult stem cells comprising very small embryonic like stem cells from autologous plasma or allogeneic plasma; D5W; glutathione; methylcobalamin; and regular insulin.2. A formulation as recited in wherein the formulation consists of a mixture of approximately 75% by volume human plasma claim 1 , 15% by volume D5W claim 1 , 5% by volume glutathione claim 1 , 4% by volume methylcobalamin claim 1 , and less than 1% by volume regular insulin.3. A formulation delivery apparatus claim 1 , consisting of: a syringe having a reservoir and a dispensing tip; and', 'a catheter selectively attached to the dispensing tip of the syringe., 'an intranasal delivery device, comprising4. A formulation delivery apparatus as recited in wherein the dispensing tip is an atomizing dispensing tip.5. A formulation delivery apparatus as recited in wherein the catheter is configured to be inserted into a naris of a brain injury patient claim 3 , and ...

Подробнее
21-03-2019 дата публикации

Platelet collection method and platelet collection system

Номер: US20190083696A1
Автор: Masatsugu Igarashi
Принадлежит: Terumo Corp

A platelet collection method includes a step of accommodating whole blood in a first chamber (44) and performing centrifugal separation, a step of transferring a buffy coat resulting from the centrifugal separation to a second chamber (50), and a step of performing centrifugal separation on the buffy coat. Subsequently, a step of transferring a platelet-containing component resulting from the centrifugal separation to a third chamber (52) and a step of performing centrifugal separation on the platelet-containing component are executed. Also performed in the collection method are a step of introducing a platelet additive solution into the third chamber (52) and replacing plasma resulting from the centrifugal separation and a step of collecting platelets remaining in the third chamber (52) along with the platelet additive solution.

Подробнее
31-03-2016 дата публикации

Automatic Purging Of Air From A Fluid Processing System

Номер: US20160089504A1
Принадлежит:

Systems and methods are provided for processing a fluid and then returning processed fluid and/or replacement fluid to a fluid recipient. The returning fluid is monitored to detect air therein and, if air is detected, steps are taken to automatically purge the air from the returning fluid without requiring the intervention of a system operator. The system may respond to detected air by pumping the processed fluid and/or replacement fluid away from the fluid recipient and into a processed fluid reservoir, where the air is purged from the processed fluid and/or replacement fluid. Thereafter, the weight of the processed fluid reservoir may be checked to confirm that sufficient fluid has been pumped back into the reservoir to remove the air. After it has been confirmed that the air has been purged from the fluid, the system may resume pumping the fluid toward the fluid recipient. 1. A fluid processing system for processing fluid and returning processed fluid and/or a replacement fluid to a fluid recipient , the fluid processing system being configured to cooperate with a fluid flow circuit including a fluid recipient line for returning processed fluid and/or a replacement fluid from a fluid processing chamber to a fluid recipient , the fluid processing system comprising:a fluid recipient pump operable in a first direction to pump processed fluid and/or a replacement fluid through the fluid recipient line toward the fluid recipient and in a second direction to pump processed fluid and/or a replacement fluid through the fluid recipient line away from the fluid recipient;an air detection assembly configured to monitor the contents of the fluid recipient line and produce an output indicative of the presence of air in the fluid recipient line flowing toward the fluid recipient; anda controller programmed to receive the output from the air detection assembly and, upon receiving said output, automatically instruct the fluid recipient pump to operate in the second direction to ...

Подробнее
31-03-2022 дата публикации

Intelligent Intracranial Hematoma Removal and Drainage System

Номер: US20220101977A1
Принадлежит:

Disclosed is an intelligent intracranial hematoma removal and drainage system, including: an information input module, an information detection module, an intelligent module and a hematoma removal and drainage module, wherein the information input module is used for collecting preoperative data and transmitting the collected preoperative data to the intelligent module; the information detection module is used for acquiring intracranial data monitored in real time and transmitting the monitored intracranial data to the intelligent module; the intelligent module is used for receiving the data from the information input module and the information detection module, analyzing the received data to make a determination, and converting the determination into an instruction signal and transmitting the same to the hematoma removal and drainage module; and the hematoma removal and drainage module is used for receiving an instruction from the intelligent module to remove and drain intracranial hematomas, and feeding data after removal and drainage back to the intelligent module. The intelligent intracranial hematoma removal and drainage system provides corresponding bases for all treatment operations, and all signals are detected in real time, thereby ensuring the real-time monitoring of key information of a patient during an intracranial hematoma treatment process, such that all the treatment operations on the patient are controllable and precise. 1. An intelligent intracranial hematoma removal and drainage system , comprising an information input module , an information detection module , an intelligent module and a hematoma removal and drainage module , whereinthe information input module is used for collecting preoperative data and transmitting the collected preoperative data to the intelligent module;the information detection module is used for acquiring intracranial data monitored in real time and transmitting the monitored intracranial data to the intelligent module;the ...

Подробнее
05-05-2022 дата публикации

CRYSTALLIZED OXALATE DECARBOXYLASE AND METHODS OF USE

Номер: US20220133865A1
Принадлежит:

Oxalate decarboxylase crystals, including stabilized crystals, such as cross-linked crystals of oxalate decarboxylase, are disclosed. Methods to treat a disorder associated with elevated oxalate concentration using oxalate decarboxylase crystals are also disclosed. Additionally disclosed are methods of producing protein crystals.

Подробнее
05-05-2022 дата публикации

BODY FLUID COMPONENT SEPARATING DEVICE

Номер: US20220133962A1
Автор: Lee Jun Seok
Принадлежит:

A body fluid component separating device according to an embodiment may comprise: a housing; a piston which divides the housing into a first space and a second space and connects the first space and the second space via fluid-connection; and a manipulator which is coupled to the piston to be operable and is configured to maintain a pressure balance between the first space and the second space, adjust movement of the piston between a first location at which the first space has a first volume and a second location at which the first space has a second volume that is different from the first volume, and fix the piston on an arbitrary location between the first location and the second location.

Подробнее
05-05-2022 дата публикации

BIOLOGICAL FLUID PURIFICATION WITH BIOCOMPATIBLE MEMBRANES

Номер: US20220133973A1
Принадлежит: IVIVA Medical, Inc.

Disclosed are apparatus and methods for blood and other biological fluid purification using a membrane with cell containing vascular channel systems and filtration channel systems. Also disclosed are methods of making the apparatus as well as methods of making membranes.

Подробнее
19-03-2020 дата публикации

FLUID PUMPING DEVICE AND BLOOD PURIFYING APPARATUS HAVING THE SAME

Номер: US20200086031A1
Автор: Lee Jake K.
Принадлежит:

Provided is a blood purifying apparatus including a blood purifying filter in which mass transfer occurs between blood and dialysis fluid, a blood tube connecting the blood purifying filter and a patient to allow blood to flow therethrough, a dialysis fluid supply tube connected to the blood purifying filter and allowing dialysis fluid to be supplied to the blood purifying filter therethrough, a dialysis fluid discharge tube connected to the blood purifying filter and allowing dialysis fluid to be discharged from the blood purifying filter therethrough; and a fluid pumping device. The fluid pumping device further includes a plurality of chamber each having an internal space, a chamber pressurizing member disposed inside the plurality of chambers and compressing or expanding the chambers to thereby allow a fluid to flow therethrough, and a flow controller controlling a flow passage. 1. A fluid pumping device supplying or discharging dialysis fluid , the fluid pumping device comprising:a plurality of chambers each having an internal space;a chamber pressurizing member compressing or expanding the internal spaces of the plurality of chambers;a chamber pressurizing member driver driving the chamber pressurizing member, anda flow controller controlling a flow passage, whereinthe plurality of chambers comprises a first chamber, a second chamber, and a third chamber,the first chamber is connected with a first chamber tube through which a dialysis fluid is supplied to the first chamber and a second chamber tube through which a dialysis fluid is removed from the first chamber,the second chamber is connected with a third chamber tube through which a dialysis fluid is supplied to the second chamber and a fourth chamber tube through which a dialysis fluid is removed from the second chamber, andthe third chamber is connected to a fifth chamber tube through which a fluid is supplied to and removed from the third chamber,wherein the flow controller controls a flow passage through ...

Подробнее
07-04-2016 дата публикации

FLUID TRAP AND METHOD OF SEPARATING FLUIDS

Номер: US20160095986A1
Принадлежит:

A fluid trap apparatus includes an inlet configured to receive a flow of composite fluid into the apparatus. The composite fluid contains at least a first fluid and a second fluid. An outer wall defines an interior chamber. A flow diffuser is interposed within the interior chamber. The flow diffuser directs the flow of the composite fluid to circulate through the interior chamber. The first fluid and the second fluid separate as the composite fluid circulates through the interior chamber. A method of separating a first fluid from a second fluid includes introducing a flow of composite fluid into a separate chamber. A pressure gradient is created within the separation chamber. A flow diffuser is interposed in a flow path between an inlet and an outlet. The flow diffuser directs the flow of the composite fluid within the separation chamber. The first fluid and the second fluid are separated. 1. A fluid trap apparatus comprising:an outer wall defining an interior chamber;an inlet extending from the outer wall into the interior chamber, the inlet configured to receive a flow of a composite fluid into the apparatus, the composite fluid having at least a first fluid and a second fluid;a flow diffuser interposed centrally within the interior chamber and adjacent the inlet, the flow diffuser configured to change a direction of a flow of the composite fluid to separate the first fluid and the second fluid as the composite fluid circulates through the interior chamber;a first outlet integrated with the outer wall, the first outlet configured to expel a flow of the separated first fluid out of the fluid trap apparatus; anda second outlet integrated with the outer wall, the second outlet configured to expel a flow of the separated second fluid out of the fluid trap apparatus.2. The fluid trap apparatus of claim 1 , further comprising an outlet seal configurable to at least partially occlude the first outlet.3. The fluid trap apparatus of claim 2 , wherein the second outlet ...

Подробнее
05-04-2018 дата публикации

Flash Activated Passive Shielding Needle Assembly

Номер: US20180092585A1
Принадлежит:

A safety needle device includes a housing including a passageway with a needle cannula extending therefrom. A shielding member is movable between a first position in which a puncture tip of the needle cannula is exposed therefrom and a second position in which the puncture tip of the needle cannula is encompassed therein. The shielding member is maintained in the first position against a biasing force which biases the shielding member toward the second position. A fluid and/or a temperature activation material is associated with the shielding member and is adapted to deform upon contact with a fluid medium and/or a certain temperature or temperature range. The fluid medium flowing through the needle cannula causes the fluid activation material to deform, such as through expansion, thereby releasing the shielding member from the first position and allowing a drive member to bias the shielding member toward the second position. 1. A needle assembly , comprising:a housing including a passageway extending therethrough and a needle cannula having a puncture tip extending from a forward end thereof;a shielding member movable with respect to the housing between a first position in which the puncture tip of the needle cannula is exposed and a second position in which the puncture tip of the needle cannula is shielded by the shielding member, the shielding member maintained in the first position against a biasing force provided by a drive member biasing the shielding member toward the second position;an activation material associated with the shielding member and adapted to deform upon direct contact with a fluid flowing through the passageway of the housing; anda movable actuator located within the passageway,wherein the fluid flowing through the passageway of the housing causes the activation material to deform and cause the actuator to move, thereby releasing the shielding member from the first position and causing the drive member to bias the shielding member toward the ...

Подробнее
09-04-2015 дата публикации

Diaphragm Pumps and Pumping Systems

Номер: US20150098846A1
Автор: Orr Troy J.
Принадлежит:

A process fluid pump can include a pump chamber, an inlet valve, and an outlet valve. Diaphragm regions can define at least a portion of each of the pump chamber, the inlet valve, and the outlet valve. The diaphragm regions can each have an actuation region with a surface that is convexly shaped when the formed actuation region is in a natural unstressed first state, and each formed actuation region can be actuated by a motive fluid to transition to a second state in which the surface is non-convexly shaped. 129-. (canceled)30. A medical fluid pumping apparatus comprising:a first member defining first, second, and third cavities;a second member defining a first cavity, the second member being disposed adjacent the first member such that the first cavity of the second member is aligned with the first cavity of the first member;a first preshaped diaphragm region disposed between the first and second members, the first preshaped diaphragm region cooperating with the first cavity of the first member to at least partially define a motive fluid portion of a pumping chamber, the first preshaped diaphragm region cooperating with the first cavity of the second member to at least partially define a medical fluid portion of the pumping chamber, the first preshaped diaphragm separating the motive fluid portion of the pumping chamber from the medical fluid portion of the pumping chamber;a second preshaped diaphragm region disposed between the first and second members, the second preshaped diaphragm region cooperating with the second cavity of the first member to at least partially define a motive fluid portion of an inlet valve, the second preshaped diaphragm region cooperating with the second member to at least partially define a medical fluid passage of the inlet valve, the second preshaped diaphragm region separating the motive fluid portion of the inlet valve from the medical fluid passage of the inlet valve, the second preshaped diaphragm region being configured to have a ...

Подробнее
12-05-2022 дата публикации

TREATING COVID-19 UTILIZING EXTRACORPOREAL RADIOFREQUENCY

Номер: US20220143292A1
Автор: Felder Mitchell S.
Принадлежит:

An embodiment provides a method for treating a body fluid of a patient with Covid-19, including: removing the body fluid from a patient, wherein the body fluid comprises a Covid-19 targeted pathogenic antigen (TPA); applying a treatment to the body fluid, wherein the treatment comprises an antibody that joins with the Covid-19 targeted pathogenic antigen in the body fluid to form an antibody-TPA complex, wherein the antibody comprises a radiofrequency absorption enhancer forming an antibody-radio frequency enhancing moiety-virion complex (ARFVC); removing the ARFVC from the body fluid using a radiofrequency source; and returning the body fluid to the patient. Other aspects are described and claimed. 1. A method for treating a body fluid of a patient with Covid-19 , comprising:removing the body fluid from a patient, wherein the body fluid comprises a Covid-19 targeted pathogenic antigen (TPA);applying a treatment to the body fluid, wherein the treatment comprises an antibody that joins with the Covid-19 targeted pathogenic antigen in the body fluid to form an antibody-TPA complex, wherein the antibody comprises a radiofrequency absorption enhancer forming an antibody-radio frequency enhancing moiety-virion complex (ARFVC);removing the ARFVC from the body fluid using a radiofrequency source; andreturning the body fluid to the patient.2. The method of claim 1 , wherein the Covid-19 targeted pathogenic antigen is selected from the group consisting of: Covid-19 spike glycoprotein claim 1 , Covid-19 M-Protein claim 1 , Covid-19 Hemagglutinin-esterase dimer claim 1 , Covid-19 Envelope claim 1 , Covid-19 E-Protein claim 1 , Covid-19 N-Protein claim 1 , nsp (non-structural protein) 12 RNA-dependent RNA polymerase (nsp 12) claim 1 , nsp (non-structural protein) 7 claim 1 , nsp 8 claim 1 , nsp 14 claim 1 , nsp 12-nsp 7-nsp 8 complex claim 1 , nsp7-nsp8 complex claim 1 , nsp10-nsp14 complex claim 1 , and nsp10-nsp16 complex.3. The method of claim 1 , wherein the radiofrequency ...

Подробнее
05-04-2018 дата публикации

SEPARATION AND CONCENTRATION OF PARTICLES

Номер: US20180093023A1
Принадлежит:

Described are devices, methods, and kits for controlled incremental filtration (CIF), as well as methods of designing CIF devices. For example, a method for CIF may modulate a concentration of particles of a desired size in a fluid. The fluid including the particles may be flowed along a flow path through a central channel to contact a plurality of gaps that fluidically couple the central channel to at least one adjacent side channel network. Flow resistance may be decreased along at least a portion of the flow path effective to modulate the concentration of particles. The method may include selecting the plurality of gaps to be larger than the particles. The method may include causing a consistent flow fraction fin the central channel to traverse each gap in the plurality of gaps and flow through the at least one side channel network along the flow path. 1. A controlled incremental filtration (CIF) device , comprising:a. a fluid exchange module in a first substrate, the fluid exchange module comprising a corresponding first microfluidic channel and a first array of island structures in the first microfluidic channel, the first array of island structures being arranged in one or more rows that extend along a longitudinal direction of the first microfluidic channel, each island structure in a row being spaced apart from an adjacent island structure in the row to form an opening,b. wherein the first array of island structures in the fluid exchange module is configured and arranged to shift portions of fluid through the opening between adjacent island structures within a row; anda particle concentration module, the particle concentration module comprising a corresponding second microfluidic channel and a second array of island structures, each island structure in the second array of island structures being spaced apart from an adjacent island structure in the second array of island structures to form an opening,c. wherein the second array of island structures in each ...

Подробнее
13-04-2017 дата публикации

IRREVERSIBLY CLOSABLE FLOW CONTROL CLAMP

Номер: US20170100578A1
Принадлежит:

A flow control clamp having a first member and a second member movable from a first open position to a second irreversibly closed position wherein flow through a tube associated with the clamp is irreversibly prevented and cannot be restored. Systems and methods using such clamps are also disclosed. 136-. (canceled)37. A fluid processing set comprising:a container adapted for receiving biological fluid from a donor;a donor access device;a tubing segment defining a flow path that is in flow communication with said container and said access device; anda flow control clamp associated with said tubing segment, said clamp comprising:a body having a first leg and a second leg, said legs being movable from a first spaced apart position to a second irreversibly closed position wherein one of said first and second legs includes in an inwardly extending member having an engagement member and the other of said first and second legs includes a pair of inwardly extending members, one of said pair of inwardly extending members including a first surface engaged by said engagement member when said device is in said second irreversibly closed position and the other of said pair of inwardly extending members limits movement of said inwardly extending member having said engagement member away from said first surface and prevents disengagement of said engagement member from said engagement surface;at least one opening provided in said body for receiving said tubing segment therethrough and between said legs; andat least one tube contacting member carried by one of said legs for clamping said tubing segment when said legs are in the second irreversibly closed position.38. The device of wherein said pair of inwardly extending members define a space therebetween claim 37 , whereby movement of said legs from said spaced apart position to said irreversibly closed position introduces said inwardly extending member having said engagement member into said space.39. The fluid processing set of ...

Подробнее
04-04-2019 дата публикации

Wearable Filtrating Artificial Kidney Device

Номер: US20190099536A1
Автор: ZHAO Changsheng
Принадлежит:

A wearable filtrating artificial kidney device, comprising a transfusion inlet (), a blood pump (). an arterial pressure detector (), a blood filter (), a venous pressure detector () and an air detector (), wherein the transfusion inlet (), the blood pump (), the arterial pressure detector (), a resin hemoperfusion apparatus (), an active carbon hemoperfusion apparatus (), the blood filter (), the venous pressure detector () and the air detector () are connected sequentially; a liquid waste outlet of the blood filter () is connected with an ultrafiltration control pump (). Glomerulus filtration can be simulated to achieve the goal of removing toxins and excessive moisture in the blood by virtue of ultrafiltration of the blood filter (). A dialyzate and a complicated dialyzate circulating device are not used for the device, so that the volume and weight of the device can be reduced greatly, and the device can be worn conveniently. The device is simple in structure, easy in operation and low in cost. 1123478912. A wearable filtrating artificial kidney device , comprising a blood pipeline , wherein the blood pipeline is sequentially provided with a blood inlet switch () , a transfusion inlet () , a blood pump () , an arterial pressure detector () , a blood filter () , a venous pressure detector () , an air detector () , and a blood outlet switch () in a blood flowing direction;{'b': 7', '10', '11, 'the blood filter () includes an inlet, an outlet and a liquid waste outlet, the inlet and the outlet are connected with the blood pipeline, the liquid waste outlet is connected with a liquid waste pipeline on which an ultrafiltration control pump () and a liquid waste switch () are arranged,'}{'b': 4', '8', '7', '9, 'the arterial pressure detector () and the venous pressure detector () are respectively used for detecting the pressure at an inlet end and an outlet end of the blood filter (), and the air detector () is used for detecting the amount of bubbles in the returned ...

Подробнее
04-04-2019 дата публикации

SYSTEMS AND METHODS FOR MONITORING AND CONTROLLING FLUID BALANCE DURING A BIOLOGICAL FLUID PROCEDURE

Номер: US20190099541A1
Принадлежит:

Described is a method for controlling fluid volume balance. A controller is configured with a first set of inputs comprising a hematocrit, a total blood volume, and an ACD ratio. A maximum extracorporeal RBC amount during the procedure is estimated based on the first set of inputs. A fluid circuit is primed with a priming fluid. Whole blood is drawn from a blood source and separated into a RBC component, a target cell component, and a plasma component. The target cell component is directed to a product container. The product container comprising the target cell component is treated. A treated target cell component, a portion of the RBC component remaining in the fluid circuit, and/or a portion of the plasma component remaining in the fluid circuit are returned to the blood source. A first response action is provided if the maximum extracorporeal RBC amount estimated is above a programmed limit. 1. A system for monitoring and controlling fluid balance during an extracorporeal photopheresis procedure , comprising:a disposable fluid circuit comprising a product container configured to receive a target cell component;a separator configured to work in association with the disposable fluid circuit, the separator comprising a chamber configured to rotate about a rotational axis and convey whole blood from a blood source into an inlet region of the chamber for separation into a red blood cell component, a plasma component, and the target cell component; estimate an end-of-procedure fluid balance by calculating a total volume of anticoagulant solution having a citrate concentration to be used for the procedure, wherein the end-of-procedure fluid balance is estimated based on manual or automatic inputs comprising an ACD ratio relating unanticoagulated extracorporeal whole blood to anticoagulant solution, an amount of whole blood to process, a citrate infusion threshold rate, a patient body weight associated with the blood source, and a total blood volume of the blood source ...

Подробнее
04-04-2019 дата публикации

SYSTEMS AND METHODS FOR RETURNING TREATED MONONUCLEAR CELLS TO A BLOOD SOURCE

Номер: US20190099544A1
Автор: Abedin Tanima Jahan
Принадлежит:

A method for treating mononuclear cells for an extracorporeal photopheresis procedure, driven and adjusted by a microprocessor-based controller, comprising the steps of priming a fluid circuit with priming fluid, directing whole blood derived from a blood source into the fluid circuit, separating the whole blood into a red blood cell component, a mononuclear cell component, and a plasma component, returning a first portion of the red blood cell component and a first portion of the plasma component to the whole blood, adding a photoactivation agent to the mononuclear cell component to create an agent-added mononuclear cell component, irradiating the agent-added mononuclear cell component to create a photoactivated mononuclear cell component, and incubating for a period of time a first portion of the photoactivated mononuclear cell component to create an incubated photoactivated mononuclear cell component. 1. A method for treating mononuclear cells for an extracorporeal photopheresis procedure , driven and adjusted by a microprocessor-based controller , comprising the steps of:priming a fluid circuit with priming fluid;directing whole blood derived from a blood source into the fluid circuit;separating the whole blood into a red blood cell component, a mononuclear cell component, and a plasma component;returning a first portion of the red blood cell component and a first portion of the plasma component to the whole blood;adding a photoactivation agent to the mononuclear cell component to create an agent-added mononuclear cell component;irradiating the agent-added mononuclear cell component to create a photoactivated mononuclear cell component; andincubating for a period of time a first portion of the photoactivated mononuclear cell component to create an incubated photoactivated mononuclear cell component.2. The method of claim 1 , further comprising:retaining a second portion of the red blood cell component and a second portion of the plasma component within the fluid ...

Подробнее
02-06-2022 дата публикации

Systems And Methods For Collecting Mononuclear Cells

Номер: US20220168485A1
Принадлежит:

Fluid processing assemblies and methods are provided for mononuclear cell collection. Mononuclear cells are separated from red blood cells in a blood separation chamber, with the mononuclear cells and then the red blood cells exiting the chamber via an outlet port. The mononuclear cells and then the red blood cells enter an outlet flow path that is in fluid communication with a mononuclear cell collection container. The outlet flow path includes a visual indicium, which an operator may use to determine the position of the red blood cells within the outlet flow path and when to end mononuclear cell collection by preventing fluid communication between the outlet flow path and the mononuclear cell collection container. 126-. (canceled)27. A fluid processing assembly configured for use in combination with a fluid processing system for separating mononuclear cells from red blood cells , comprising:a blood separation chamber configured to separate mononuclear cells from red blood cells and including an outlet port configured to accommodate the flow of mononuclear cells and then red blood cells exiting the blood separation chamber;a mononuclear cell collection container; andan outlet flow path extending between the outlet port and the mononuclear cell collection container, wherein the outlet flow path includes a visual indicium upstream of the mononuclear cell collection container positioned to indicate that fluid communication between the outlet flow path and the mononuclear cell collection container is to be prevented upon red blood cells flowing through the outlet flow path reaching a location identified by the visual indicium.28. The fluid processing assembly of claim 27 , wherein the outlet flow path is defined bya rigid cassette,an upstream flexible tubing extending between the outlet port and the cassette, anda downstream flexible tubing extending between the cassette and the mononuclear cell collection container, with the visual indicium identifying a location ...

Подробнее
02-06-2022 дата публикации

SYSTEMS AND METHODS FOR OPTIMIZATION OF PLASMA COLLECTION VOLUMES

Номер: US20220168486A1
Принадлежит: Fenwal, Inc.

A system for collecting plasma comprises a separator to separate whole blood from a donor into a plasma product and a second blood component, an anticoagulant line to combine anticoagulant with the whole blood, a touchscreen, and a controller. The controller is configured to receive donor parameters electronically from a donor management system. The controller is configured to use a target volume for raw plasma which is based at least in part on donor height and weight used to calculate total donor blood volume, the target volume for raw plasma based on the total donor blood volume. The controller is configured to control the system to operate draw and return phases to withdraw whole blood from a donor and return the second blood component to the donor until a volume of raw plasma in the collection container equals the target volume of raw plasma. 1. A system for collecting plasma , comprising:a separator configured to separate whole blood into a plasma product and a second blood component comprising red blood cells, the separator having a plasma output port coupled to a plasma line configured to send the plasma product to a plasma product collection container;a donor line configured to introduce the whole blood from a donor to the separator;an anticoagulant line coupled to an anticoagulant source configured to combine anticoagulant with the whole blood from the donor based on an anticoagulant ratio (ACR);a touchscreen configured to receive input from an operator; and{'sub': RP', 'RP', 'PP, 'a controller configured to control operation of the system, the controller coupled to the touchscreen and configured to receive donor parameters electronically from a donor management system, to use a target volume for raw plasma which is based at least in part on donor height and weight used to calculate total donor blood volume, the target volume for raw plasma based on the total donor blood volume, wherein the target volume for raw plasma is set prior to blood collection from ...

Подробнее
21-04-2016 дата публикации

System and Method for the Re-Anticoagulation of Platelet Rich Plasma

Номер: US20160106908A1
Принадлежит:

A method for the re-anticoagulation of platelet rich plasma in a blood apheresis system includes priming the blood apheresis system with anticoagulant, such that a volume of anticoagulant is transferred to a PRP container. The method may then transfer the anticoagulant within the PRP container to a red blood cell container, and collect a volume of platelet rich plasma within the PRP container. The platelet rich plasma may be collected in a plurality of cycles. Between collection cycles, the method may transfer a portion of the volume of anticoagulant from the red blood cell container to the PRP container. 1. A method for the re-anticoagulation of platelet rich plasma in a blood apheresis system , the method comprising:priming the blood apheresis system with anticoagulant such that a volume of anticoagulant is transferred to a PRP collection container;transferring the anticoagulant within the PRP collection container to a second container;collecting a volume of platelet rich plasma within the PRP collection container, the volume of platelet rich plasma being collected in a plurality of cycles;transferring at least a portion of the volume of anticoagulant from the second container to the PRP collection container between each of the plurality of cycles.2. A method according to claim 1 , wherein the at least a portion of the volume of anticoagulant transferred to the PRP collection container is proportional to an amount of platelet rich plasma collected in the preceding cycle.3. A method according to claim 1 , wherein priming the blood apheresis system with anticoagulant includes priming an anticoagulant line and a donor line filter with anticoagulant.4. A method according to claim 3 , wherein priming the blood apheresis system includes transferring the anticoagulant within the donor line filter to the second container.5. A method according to claim 4 , wherein the anticoagulant within the donor line filter is transferred to the second container at the start of the ...

Подробнее
19-04-2018 дата публикации

Systems, devices, and methods for bodily fluid separation materials

Номер: US20180104656A1
Принадлежит: Theranos IP Co LLC

In one embodiment described herein, a bodily fluid separation material is provided comprising a formed component capture region and a bodily fluid pass-through region. The pass-through region has structures with a reduced liquid leaching quality relative to than the capture region, wherein during separation material use, bodily fluid enters the capture region prior to entering the pass-through region. Optionally, a bodily fluid pass-through region has a reduced amount of liquid leaching material relative to than the capture region.

Подробнее
02-04-2020 дата публикации

Neuraxial Connector

Номер: US20200101237A1
Принадлежит:

Described is a medical adapter assembly comprising an end including a neuraxial fitting that is not directly connectable to a standard luer fitting, an opposing end including a fitting connectable to an intravenous medical device, and a check valve that allows fluid flow from the end with the standard luer fitting to the end with the neuraxial fitting, but prevents fluid flow from the end with the neuraxial fitting to the end with the standard luer fitting. Methods of using the medical adapter assembly and kits containing the medical adapter assembly are also described. 1. A medical adapter assembly comprising:a first end comprising a neuraxial fitting that is not directly connectable to a standard luer fitting;a second end opposite the first end, the second end comprising a fitting connectable to a of an intravenous medical device by a slip-type connection; anda check valve that allows fluid flow from the second end to the first end and prevents fluid flow from the first end to the second end.2. The medical adapter assembly of claim 1 , wherein the check valve is disposed between the first end and the second end.3. The medical adapter assembly of claim 2 , wherein the check valve is integrally formed with the first end and the second end.4. The medical adapter assembly of claim 3 , wherein the neuraxial fitting protrudes from the check valve.5. The medical adapter assembly of claim 1 , wherein the neuraxial fitting is a female neuraxial fitting.6. The medical adapter assembly of claim 1 , wherein the fitting on the second end is adapted to receive catheter tubing by a friction fit.7. The medical adapter assembly of claim 1 , wherein the check valve is a one-way valve that allows fluid flow in only one direction.8. The medical adapter assembly of claim 7 , wherein fluid flows from the second end through the check valve to the first end.9. The medical adapter assembly of claim 7 , wherein the one-way valve is selected from the group consisting of a duckbill valve ...

Подробнее
02-04-2020 дата публикации

Biological component collection kit and blood component collection system

Номер: US20200101404A1
Автор: Masatsugu Igarashi
Принадлежит: Terumo Corp

A third cassette ( 28 ) of a blood component collection kit ( 12 ) is equipped with a third cassette main body ( 29 ) in which a flow path (F) is formed together with having a filter accommodating unit ( 86 ), and a filter member ( 88 ) disposed in the filter accommodating unit ( 86 ). The flow path (F) includes a red blood cell line (f 1 ) in which red blood cells flow, a preservation solution line (f 2 ) in which a preservation solution flows, a confluence section (f 3 ) in which the red blood cells and a preservation solution are made to merge together, a mixed liquid line (f 4 ) through which a mixed liquid of the red blood cells and the preservation solution flows, and a filter chamber (f 5 ) formed inside the filter accommodating unit ( 86 ).

Подробнее
20-04-2017 дата публикации

SELF-CONTAINED DISPOSABLE TUBING SET FOR STERILE PREPARATION OF CELLS BY CULTURING, CENTRIFUGATION, AND COLUMN CHROMATOGRAPHY

Номер: US20170107480A1
Принадлежит: Miltenyi Biotec GmbH

The invention relates to a system, comprising: a) a sample processing unit, comprising an input port and an output port coupled to a rotating container having at least one sample chamber, the sample processing unit configured provide a first processing step to a sample or to rotate the container so as to apply a centrifugal force to a sample deposited in the chamber and separate at least a first component and a second component of the deposited sample; and b) a sample separation unit coupled to the output port of the sample processing unit, the cell separation unit comprising separation column holder (), a pump () and a plurality of valves (-) configured to at least partially control fluid flow through a fluid circuitry and a separation column () positioned in the holder, the separation column configured to separate labeled and unlabeled components of sample flowed through the column. 125-. (canceled)27. A tubing set according to claim 26 , configured so that cells can be fed into the processing chamber while the rotatable container is being centrifuged.28. A tubing set according to claim 26 , wherein the processing chamber is configured for culturing the cells.29. A tubing set according to claim 26 , wherein the rotatable container is configured such that gases can enter and leave the processing chamber while maintaining sterility and without stopping centrifugation.30. A tubing set according to claim 26 , wherein the processing chamber comprises a plurality of surfaces perpendicular to the rotational axis upon which cells can be cultured.31. A tubing set according to claim 26 , wherein the rotatable container has a window configured for optical observation of material in the processing chamber during centrifugation.32. The tubing set according to claim 31 , wherein the window extends radially in the bottom or top of the rotatable container from a position adjacent to the rotation axis to a position near the perimeter of the container.33. The tubing set according ...

Подробнее
28-04-2016 дата публикации

Dialysis Systems and Methods

Номер: US20160114092A1
Принадлежит: Fresenius Medical Care Holdings Inc

This invention relates to dialysis systems and methods. In some implementations, a method includes applying vacuum pressure to a device of a dialysis system, and then determining, based on a detected fluid level or measured pressure, whether the device is functioning properly.

Подробнее
28-04-2016 дата публикации

METHODS AND SYSTEMS FOR COLLECTING MONONUCLEAR CELLS

Номер: US20160114095A1
Принадлежит:

A method for obtaining MNCs is set forth. The method includes: separating mononuclear cells from a biological fluid that includes red blood cells, plasma and platelets and collecting a targeted number of mononuclear cells in a suspension including plasma and residual red blood cells and platelets; concentrating the separated mononuclear cells; removing plasma from the concentrated mononuclear cells until the amount of residual plasma remaining with the concentrated mononuclear cells reaches a pre-determined volume; and adding a crystalloid solution to the concentrated mononuclear cells. Related apparatus and resultant MNC products are also disclosed. 1. A method for obtaining mononuclear cells and preparing the mononuclear cells for photopheresis with a separation device comprising:a) separating mononuclear cells from a biological fluid that includes red blood cells, plasma and platelets;b) collecting a targeted number of mononuclear cells in a suspension including plasma and residual red blood cells and platelets;c) concentrating said separated mononuclear cells;d) removing plasma from the concentrated mononuclear cells until the amount of residual plasma remaining with the concentrated mononuclear cells reaches a pre-determined volume; ande) adding a crystalloid solution to the concentrated mononuclear cells.2. The method of wherein said volume of residual plasma remaining with said concentrated mononuclear cells is less than or equal to (≦) 50 ml.3. The method of wherein the concentrated mononuclear cells after adding the crystalloid solution has a hematocrit of less than or equal to (≦) 2%.4. The method of wherein crystalloid solution is added to the concentrated mononuclear cells so that the volume % of plasma is less than or equal to (≦) 25%.5. The method of in which from 150 mL to 200 mL of crystalloid solution is added to the suspension.6. The method of further comprising collecting said mononuclear cells in a collection container suitable for irradiation of ...

Подробнее
09-06-2022 дата публикации

Methods and Systems for Increased Production of Stem Cells

Номер: US20220175832A1
Автор: Ovokaitys Todd Frank
Принадлежит:

Platelet rich plasma containing human very small embryonic-like stem cells (hVSEL) is treated with amplitude-modulated pulses of laser light having a predefined wavelength for a predefined time period, where the predefined wavelength ranges from 300 nm to 1000 nm. Treatment of the platelet rich plasma using this method results in an unexpectedly high degree of proliferation of the hVSEL in the platelet rich plasma, resulting in reduction of biological age, when administered to a patient. 1. A method of reducing biological age of a patient comprising:proliferating stem cells of the patient, wherein the proliferation comprises preparing platelet rich plasma containing stem cells and treating the platelet rich plasma containing stem cells with modulated pulses of laser light having a predefined wavelength and for a predefined period of time; and,administering the treated platelet rich plasma to the patient.2. The method of claim 1 , wherein preparing the platelet rich plasma comprises:adding the patient's blood into a plurality of tubes;centrifuging the plurality of tubes at a predefined g force for a predefined period of time to produce the platelet rich plasma; andaliquoting the produced platelet rich plasma into a sterile tube.3. The method of wherein the centrifuging the plurality of tubes further comprises shaking the plurality of tubes after centrifuging claim 2 , wherein the aliquoting the produced platelet rich plasma into a sterile tube further comprises shaking the sterile tube after aliquoting claim 2 , and wherein the treating the platelet rich plasma containing stem cells with modulated pulses of laser light further comprises shaking the platelet rich plasma after treating with modulated pulses of laser light.4. (canceled)5. (canceled)6. (canceled)7. The method of claim 1 , wherein the treatment of the platelet rich plasma is carried out in minimum background white light conditions.8. The method of claim 1 , wherein the predefined wavelength ranges from ...

Подробнее
09-06-2022 дата публикации

BLOOD PERFUSION DEVICE

Номер: US20220176028A1
Автор: Bornemann Reinhard
Принадлежит:

The present invention relates to various methods of treatment using a novel blood perfusion device. The blood perfusion device comprises a perfusion chamber comprising at least one compartment A and at least one compartment B, compartment A comprising a first opening which is in direct fluid communication to a second opening, wherein the first opening of compartment A is in direct fluid communication to a first port of the perfusion chamber and the second opening of compartment A is in direct fluid communication to a second port of the perfusion chamber; and compartment B comprising a first opening which is in direct fluid communication to a second opening, wherein the first opening of compartment B is in direct fluid communication to a third port of the perfusion chamber and the second opening of compartment B is in direct fluid communication to a fourth port of the perfusion chamber, wherein compartment A is separated from compartment B by at least one membrane, said membrane being configured to prevent cells from crossing the membrane. 11. A blood perfusion device comprising a perfusion chamber () comprising at least one compartment A and at least one compartment B ,{'b': 4', '2', '3, '(a) compartment A () comprising a first opening which is in direct fluid communication to a second opening, wherein the first opening of compartment A is in direct fluid communication to a first port () of the perfusion chamber and the second opening of compartment A is in direct fluid communication to a second port () of the perfusion chamber; and'}{'b': 7', '5', '6, '(b) compartment B () comprising a first opening which is in direct fluid communication to a second opening, wherein the first opening of compartment B is in direct fluid communication to a third port () of the perfusion chamber and the second opening of compartment B is in direct fluid communication to a fourth port () of the perfusion chamber;'}wherein compartment A is separated from compartment B by at least one ...

Подробнее
26-04-2018 дата публикации

New Standardizations & Medical Devices For The Preparation Of Platelet Rich Plasma (PRP) Or Bone Marrow Centrate (BMC) Alone Or In Combination With Hyaluronic Acid

Номер: US20180110917A1
Автор: TURZI ANTOINE
Принадлежит:

The present invention is related to the field of tissue regeneration. It concerns more particularly new standardizations and medical devices for the preparation of A-PRP, PRP, BMC, fat tissue, alone or in combination with a biomaterial or cell extract. 117-. (canceled)18. A system for the preparation of a cell composition , comprising: an opening;', 'an anticoagulant;', 'a thixotropic gel adapted to separate blood by forming a barrier between a platelet rich plasma and red blood cells when the tube is centrifuged for a length of time;', 'a stopper sealing the opening and keeping the anticoagulant and the thixotropic gel sterile in the tube;, 'a tube having an opening;', 'a biomaterial;', 'a stopper sealing the opening and keeping the biomaterial sterile in the container;, 'a container having a first connector adapted to connect to the tube;', 'a second connector adapted to connect to the container;, 'a transfer device havinga cell composition formed by mixing the platelet rich plasma and the biomaterial when the tube and container are both connected to the transfer device and the platelet rich plasma transfers from the tube to the container in a closed circuit to maintain sterility.19. The system of claim 18 , wherein the container is under vacuum pressure claim 18 , the vacuum pressure facilitating transfer of the platelet rich plasma from the tube to the container.20. The system of claim 19 , wherein the container comprises a syringe or tube.21. The system of claim 18 , wherein the biomaterial comprises a hyaluronic acid.22. The system of claim 18 , wherein the biomaterial comprises at least one of a chitosan claim 18 , a silk protein claim 18 , and a fibroin.23. The system of claim 18 , further comprising a collection device for collecting the blood from a patient;wherein the tube is under vacuum pressure and the collection device is adapted to pierce the stopper of the tube so that the vacuum pressure facilitates aspiration of the blood from the patient.24. A ...

Подробнее
27-04-2017 дата публикации

SYSTEM AND METHOD FOR FREEZE-DRYING AND PACKAGING

Номер: US20170113824A1
Принадлежит:

A system and method for protecting biological or other material from contamination through the steps of filling, freeze-drying, packaging, storing and use are disclosed. A system can include a flexible container, a membrane configured to transmit air or solvent vapor out of the flexible container, and a membrane frame supporting the membrane and engaged with at least one column member. The at least one column member can be configured to maintain the membrane and the membrane frame a spaced distance from one or more contents received within the flexible container. Upon application of a downward force, the at least one column member can assume a collapsed configuration. A method can include inserting a biological material, for example, into a flexible container, freeze-drying the biological material, moving the freeze-dried biological material to a portion of the flexible container that includes at least one port, and sealing the biological material within the portion. 1. A method , comprising:inserting a biological material into a flexible container in which a first container side includes a gas-permeable membrane;freeze-drying the biological material in the flexible container, including allowing air or solvent vapor to escape the flexible container through the membrane;moving the freeze-dried biological material to a portion of the flexible container spaced from the membrane; andsealing the biological material within the portion of the flexible container spaced from the membrane.2. The method of claim 1 , further comprising preventing the membrane from contacting the biological material.3. The method of claim 2 , wherein preventing the membrane from contacting the biological material includes supporting the membrane at a spaced distance from a second container side using a membrane frame and at least one column member.4. The method of claim 3 , further comprising claim 3 , prior to sealing the biological material within the portion of the flexible container spaced ...

Подробнее